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Continuous exposure of ovarian tumours to a chemotherapy drug can result in the acquisition of 
drug resistance, which ultimately leads to chemotherapy failure and the death of a great majority 
of ovarian cancer patients. While previous studies suggest that withdrawal of the chemotherapy 
drug for a period of time (the drug-free interval) can result in restored clinical sensitivity to the 
drug, it is unclear whether exposure to a new drug of contrasting mechanism of action may 
accelerate restored sensitivity to the prior drug.  In this study, we exposed a carboplatin-resistant 
ovarian tumour cell line (A2780CBN) to increasing concentrations of docetaxel (A2780CBNDXL 
cells) or we permitted the cells to grow in the absence of drug for an identical number of drug 
passages (A2780CBNCC cells).  Similarly, we exposed a docetaxel-resistant ovarian tumour cell 
line (A2780DXL) to increasing concentrations of carboplatin (A2780DXLCBN cells) or we 
permitted the cells to growth in the absence of drug for an identical period (A2780DXLCC cells).  
By measuring the sensitivity of the above cell lines to either carboplatin or docetaxel, the aim of 
my thesis studies was to compare the effects of a drug-free interval or the acquisition of new 
drug resistance on prior drug resistance in vitro. The results showed that the prior carboplatin 
resistance was not significantly altered by the acquisition of docetaxel resistance or by 
withdrawal of carboplatin. However, prior docetaxel resistance was greatly reduced by selection 
for carboplatin resistance or by prolonged docetaxel withdrawal. Microarray analysis suggests 
that the loss of docetaxel resistance may be related to down-regulated expression of the ABCB1 
and ABCB4 genes, which encode multidrug transporters. It may also relate to up-regulation of 
CYP1B1 gene expression, which encodes cytochrome P450, a phase I enzyme involved in taxane 
metabolism. The microarray analysis data also suggests that the newly established carboplatin 
iv 
resistance in A2780DXLCBN cells may be related to the expression of genes that promote cell 
survival by protecting cells from apoptotic death.  
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Chapter 1  
1. Introduction  
Ovarian cancer has a high death rate for multiple reasons 1,2. Firstly, it is often detected and 
diagnosed at an advanced stage, which is hard to treat. Typically, the disease is treated first by 
surgery, followed by adjuvant chemotherapy, although neoadjuvant chemotherapy regimens 
have been employed in some clinical settings 3–5.  The extent of surgery and the choice of 
chemotherapeutic agents vary depending upon the stage of the tumour. Among the many 
antitumour agents, extensive studies have been done to elucidate their different mechanisms of 
action in cancer cells. Secondly, tumour cells can develop resistance to chemotherapeutic drugs, 
meaning that the tumour is no longer sensitive to the administered drugs 6,7. Therefore, curability 
of ovarian cancer is seldom seen. In this chapter, an overview of ovarian cancer, including 
current treatment regimens and mechanisms of chemotherapy resistance will be discussed.  
 Ovarian Cancer  1.1
Ovarian cancer has the highest mortality rate among all female gynecological cancers. It is still 
considered to be the fifth leading cause of death for female cancer patients in North America, 
and sixth in Europe1,2. When ovarian tumours are in an early stage (Stage I), patients present no 
symptoms, which makes it difficult to discover. At this stage, studies have shown that the 5 year 
survival rate after treatment can reach as high as 90% 2. However, most cases of ovarian cancer 
are usually detected at an advanced stage (Stage III, IV) when the malignancy spreads beyond 
the ovary and obvious symptoms are exhibited8,9. These symptoms, however, are often attributed 
2 
to those preceding or occurring during menstruation or menopause, and are thus overlooked.  
According to statistics, the 5 year survival rate for stage III or stage IV ovarian cancer drops 
drastically to around 20% 10–12. 
The treatment of ovarian cancer involves both surgery and chemotherapy. At an early stage, after 
a staging procedure 2, the treatment strategy involves surgery which may be followed by 
adjuvant chemotherapy 3, depending on the grade of the tumour 13,14. The agents that are used 
range from the traditional alkylating agents (cyclophosphamide, thiotepa, melphalan, and 
bulsulfan)15,16 to more recently platinating agents (cisplatin, carboplatin, satraplatin) 17. While 
platinum-based agents remained first-line chemotherapeutic agents against ovarian cancer in the 
1990’s, a series of clinical trials in the early 2000’s favored the combination of taxanes with 
platinating agents in the treatment of ovarian cancer 18–21. In advanced stages of ovarian cancer, 
the initial responsiveness to combination therapy is as high as 70%. While a combination of 
taxanes and platinating agents has become a mainstream therapy in ovarian cancer treatment, 
there is still a high recurrence rate.  This is likely due to the acquisition of strong tumour 
resistance to both drugs, leading to chemotherapy failure. Nowadays, apart from 
chemotherapeutic agents, a number of biological and targeted therapies have been studied for 
improving outcomes for ovarian cancer 22, but prognosis remains poor for the disease 23.  
 Chemotherapeutic Agents and Their Cytotoxicity 1.2
 Platinating Agents and Cytotoxicity 1.2.1
Platinating agents are platinum-based drugs including the first generation cisplatin, the less toxic 
carboplatin, satraplatin, and many other analogues (Figure 1.1).  
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(A)                                        (B)                                  (C) 
Figure 1.1 Chemical structures of platinating agents 
Chemical structures of (A) Cisplatin, (B) Carboplatin, and (C) Satraplatin (taken from 
reference 24). 
Platinating agents are commonly used for the treatment of ovarian, lung, testicular, and head and 
neck cancers 25. The drug molecules contain leaving groups (e.g. chloride ions in cisplatin, and 
bidentate dicarboxylate ligands in carboplatin), which are replaced by water molecules in the 
cytoplasm once the drugs enter the cell. Thus, the hydrolyzed molecules become positively 
charged and are able to bind to nucleophilic DNA at the N7 atom of purines within the DNA 
structure 26,27. The resulting adducts can be grouped into 4 major categories 24. First, intrastrand 
adducts form when the platinum-based molecule cross-links with adjacent guanines, both 
adenine and guanine, or adjacent adenines. Second, this kind of crosslink can also form between 
two purines from both DNA strands, thus giving rise to interstrand adducts. Other than linkage 
between nucleobases, protein and DNA adducts can also be facilitated by platinating agents. Last, 
monoadducts can rarely form when one arm of the molecule forms a linkage to one nucleobase, 
while the other remains hydrolyzed. The majority of the cross-links are intrastrand adducts, 
especially ones between adjacent guanines (1, 2-d (GpG)) (Figure 1.2).  
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Figure 1.2  Demonstration of platinum-DNA adducts 
Demonstration of (A) monoadducts, (B) intrastrand crosslinks, (C) interstrand crosslinks, 
and (D) DNA-protein crosslinks formed by platinating agents (taken from reference 24). 
The strong crosslinks result in the bending and distortion of DNA structure. Hence, disruption of 
DNA replication, DNA repair and DNA transcription occurs 28,29. Physically, DNA and RNA 
polymerases cannot access their normal binding sites to promote DNA replication and 
transcription, respectively. Moreover, a wide range of proteins has been identified that recognize 
DNA-cisplatin adducts. One notable category is the HMG (high mobility group) domain 
proteins30 (e.g. HMG-1, HMG-2, TCF-1a) that bind DNA-cisplatin adducts. Their binding not 
only hinders DNA replication but also inhibits the repair of DNA performed by the human 
excision nuclease and other proteins 31,32. Other than HMG domain proteins, H1 histones were 
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also discovered to strongly bind to these DNA adducts, which have been shown to impact on the 
epigenetic regulation of gene expression 33. Another mechanism accounting for transcription 
inhibition is the interference with transcription factor binding to gene promoters 34,35. The human 
RNA polymerase I transcription upstream binding factor (hUBF), and TATA binding protein 
(TBP) are essentially involved in initiation of transcription. DNA adducts formed by cisplatin 
have been found to sequester these factors at the damaged sites and prevent the transcription 
process36,37. 
When DNA is damaged by cisplatin, forming bulky crosslinks with DNA, the replication fork is 
stalled and recruits the damage recognition proteins mentioned above (HMG domain proteins, 
H1 histone, hUBF, and TBP). Cell cycle progression is then delayed (cell cycle arrest) to repair 
the damage or to induce a form of programmed cell death termed apoptosis 38.  One typical 
pathway induced by DNA adduct formation is the ATR-Chk1-p53 39  pathway, where the 
damage recognition proteins activate ATR kinase, which phosphorylates Chk1 kinase. The 
protein p53 is then activated subsequently and can induce apoptosis 40. p53 is a sequence-specific 
transcription factor and tumor suppressor. It activates the downstream apoptosis pathway leading 
to tumour cell death 41. 
Apoptosis might be a result of the disruption of nuclear and mitochondrial DNA structure42. 
Mitochondria are small organelles involved in oxygen and energy metabolism in the cell and 
contain their own self-replicating DNA that encodes important proteins for oxidative 
phosphorylation 43. Since platinating agents have the strong ability to bind to mitochondrial 
DNA as well, mitochondria and oxidative pathways become susceptible to their toxicity. 
Through attacking mitochondrial DNA, platinating agents can trigger an excessive production of 
reactive oxygen species (ROS) by the catalytic effect of NADPH oxidases whose function is to 
6 
transport electrons across the mitochondrial membrane and to generate ROS 44,45. Through a 
series of cell signaling pathways, elevated levels of ROS can also lead to p53 activation46,47. 
Cisplatin attacks on mitochondria also result in depletion of glutathione (GSH), calcium uptake 
inhibition and reduction of mitochondrial membrane potential 48. 
p53 transcriptionally regulates many apoptosis-related genes 41,49. Bcl-2 (B-cell lymphoma 2), 
Bcl-XL (B-cell lymphoma-extra large), Bax (Bcl-2-associated X protein) are members of the Bcl-
2 family and are apoptosis regulator proteins 50. p53 promotes the level of BAX gene 
transcription 51 as well as the binding of pro-apoptotic Bax to a mitochondrial voltage-dependent 
anion channel (VDAC). The binding increases cytochrome c release from the mitochondria 52,53. 
Through the interaction between cytochrome c and Apaf-1 (Apoptotic protease activating factor 
1), a cascade of caspases are activated by phosphorylation, which leads to apoptosis 54. On the 
other hand, p53 transcriptionally down-regulates the expression of anti-apoptotic proteins Bcl-XL 
and Bcl-2 55. 
Cisplatin is still considered to be the most potent among the platinum-based anti-cancer agents in 
spite of its strong nephrotoxicity, which was a big concern for this first generation platinating 
agent. Its derivatives such as carboplatin and satraplatin are used as the mainline treatment of 
ovarian cancer as well. Carboplatin has a lower excretion rate, meaning its effects are longer 
lasting 56. Compared to cisplatin, carboplatin is less nephrotoxic, which is considered to be its 
greatest benefit. Cisplatin breaks down to unstable hydrolysis products which are rapidly bound 
to plasma proteins and extensively filtered, with some active secretion by the kidney.  This high 
renal concentration is thought to be the major cause of nephrotoxicity. Carboplatin may be less 
nephrotoxic than cisplatin because carboplatin is more soluble and chemically stable and binds 
more slowly to plasma proteins 57,58. 
7 
 Taxanes and Cytotoxicity 1.2.2
In the 1960’s, a natural compound was extracted from the bark of Taxen brevifolia, the Pacific 
Yew Tree, and was named Taxol (paclitaxel). Paclitaxel is highly lipophilic and consists of an 
eight-member taxane ring with a four-member oxatane ring and an ester side chain that is 
necessary for antitumour activity 59. It has been used mostly in the treatment of breast, ovarian, 
prostate, and non-small cell lung cancer 60. A semisynthetic form of the drug, docetaxel or 
Taxotere was developed and is currently widely used clinically 61. 
                                              
(A)                                                                            (B) 
Figure 1.3 Chemical structure of taxanes.  
Chemical structures of (A) Paclitaxel and (B) Docetaxel (taken from reference 61). 
During cell proliferation, metaphase occurs when condensed chromosomes line up at the 
equatorial plate within cells. The chromosomes are attached by microtubules stretched from two 
poles of the cells, which facilitate chromosome segregation equally between two daughter cells 
62. These microtubules are the targets of taxanes. To be more precise, taxanes bind to β-tubulin 
8 
subunits of microtubules to manifest their function 63,64. Most commonly, the cytotoxicity of 
taxanes is a result of the binding of drug to microtubules. It has been known that taxanes 
accelerate microtubule polymerization, without permitting depolymerisation that normally 




                               
 
                 
         (D) Polymerization (Rescue) and depolymerisation (Catastrophe) of microtubules 
Figure 1.4 Mitosis and microtubules  
(A) metaphase, (B) anaphase, and (C) microtubules (taken from reference 66); (D) The 
micro-structure of microtubules and their dynamics: polymerization (rescue) and 
depolymerisation (catastrophe) (taken from reference 67).  
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The consequent arrest of the cell cycle at mitotic phase has been considered to be the initial 
cause of paclitaxel-induced cytotoxicity 68,69. For example, when microtubules are stabilized, it 
activates JNK/SAPKs (c-Jun N-terminal kinases/stress-activated protein kinases) and promotes 
apoptosis70. The mitotic arrest also causes phosphorylation of Bcl-2, inhibiting its anti-apoptotic 
effect 71,72. Moreover, studies have shown that after the mitotic spindle is stabilized, the cell 
enters a multinucleated state. The downstream events are not clear now, but activation of p53 is 
observed, which leads to subsequent apoptosis 73,74. 
Paclitaxel can also directly initiate apoptosis in cells at the transcriptional level. High 
concentrations of paclitaxel can induce an up-regulation of pro-apoptotic Bax and a down-
regulation of anti-apoptotic Bcl-XL 75. This then promotes apoptosis through the induction of 
cytochrome c release, binding to Apaf-1, and caspase-3 activation. 
Taxanes are metabolized by cytochrome P450 (CYP450) enzymes mainly in the liver 76. There 
are studies showing the pharmacokinetics of taxanes, where CYP3A catalyzes oxidation of 
paclitaxel, forming 6-alpha-hydroxypaclitaxel which is an inactive form of the drug 77,78. The 
choice of use between paclitaxel and docetaxel varies. There is some evidence that docetaxel is 
more potent at killing cancer cells than paclitaxel, since the former has a longer retention time 
due to its greater uptake and reduced efflux from tumour cells 79. However, docetaxel can often 
have more severe side effects than paclitaxel, mainly due to its ability to induce strong 
neutropenia (low white blood cell count).  This, however, can be effectively managed by using 
pegfilgrastim to stimulate new white blood cell growth 80,81. All in all, the choice between 
paclitaxel and docetaxel depends on multiple factors such as the treatment regimen, the type of 
cancer, and the health of patients 82. 
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 Combination of Platinating Agents and Taxanes 1.2.3
Combining platinating agents and taxanes has become the standard of care for the treatment of 
ovarian cancer patients. In comparing single agent therapy to combination therapy, the overall 
survival rate was much higher in the latter case. Parmar et al. 83 randomized patients into 
platinum-based and platinum/paclitaxel-based arms in 2003. The results showed that 
progression-free survival in the former arm was 9 months, while in the latter arm, it was 
significantly longer (12 months; p=0.06).  Nevertheless, such short progression-free survival 
times for both regimens underscores the need for more effective chemotherapy or other treatment 
methods for ovarian cancer patients.  The administration of these anticancer agents is usually 
through intravenous (i.v.) infusion or intraperitoneal (i.p.) injection 84.  In 1996, 410 patients with 
debulked stage III or IV tumours were randomized into two groups receiving either 
cisplatin/cyclophosphamide or cisplatin/paclitaxel chemotherapy. Results showed that 
progression-free survival at 18 vs 13 months was significantly higher in the cisplatin/paclitaxel 
group (18 months) than cisplatin/cyclophosphamide group (13 months) (P = 0.01).  Overall 
survival duration was also significantly longer in patients treated with cisplatin/paclitaxel  (38 
months vs 24 months, P < 0.001) 18.  As it became evident that carboplatin is equally effective 
with less organ toxicity than cisplatin, carboplatin took over as standard of care for the treatment 
of ovarian cancer (along with paclitaxel or docetaxel) 85. The concept of combining platinum-
based agents and taxanes was to let patients undergo administration of both to exert a strong 
synergetic effect before acquisition of resistance to either drug. A typical infusion scheme of 
carboplatin/paclitaxel is once every three weeks for 6 to 9 cycles. Recent “dose dense” regimens 
using weekly paclitaxel administration with tri-weekly carboplatin yield a better response rate 86. 
Progression-free survival was 28 months for the dose-dense regimen compared to 17.2 months 
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for the standard regimen. The overall survival rate was respectively 72.1% and 65.1% in three 
years, respectively 86. Clinician scientists have also tried to add a third anti-cancer agent to the 
regimen, but this did not show better outcomes 87.  This indicates that the carboplatin/taxane 
combination remains the most effective chemotherapy regimen to date for the treatment of 
ovarian cancer. Among the cancer patients treated with a combination of platinating agents and 
taxanes, 70% will respond to the regimen. However, even with combination chemotherapy, the 
majority of the patients that respond will experience disease recurrence, at which time the 
tumour acquires strong resistance to both platinating agents and taxanes 88. This situation calls 
for both the development of new anti-cancer agents and/or improved approaches to combat 
acquired resistance to platinating agents and taxanes.  
 Mechanisms of Resistance  1.3
 Innate vs. Acquired Resistance 1.3.1
In the beginning of treatment for ovarian cancer, approximately 30% of patients do not respond 
to adjuvant chemotherapy. These patients are said to have innate resistance, despite the lack of 
prior exposure to chemotherapy agents. While the remainder respond to treatment, the tumours 
of such patients eventually become drug resistant 89. In this situation, the cells of recurrent 
tumours are said to have acquired drug resistance.  Both resistance mechanisms remain a major 
challenge to the successful treatment of ovarian cancer.  A better understanding of the 
mechanisms underlying both innate and acquired resistance may help uncover novel approaches 
to circumvent these mechanisms. 
 Resistance in vitro vs. in vivo 1.3.2
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Multiple mechanisms are believed to be responsible for drug resistance at the cellular level, 
including gene mutations, gene amplifications or changes in the expression or activity of proteins 
that influence the uptake, efflux, targeting and metabolism of chemotherapy drugs 89–91. In 
addition, Reed and et al., and others identified epigenetic changes associated with acquired drug 
resistance 92–94. It is very important to note that many of the above mechanisms were identified 
largely through experiments on cells cultured in vitro, meaning outside the living organism. In 
these studies, cancer cells are placed in a plastic flask and are bathed in medium that contains 
nutrients and factors to promote cell survival. Thus, in contrast to cells in animals and humans 
(in vivo), cellular pathways promoting survival predominate over pathways promoting cell death 
under these ideal conditions 95,96. Thus, to truly understand resistance to chemotherapy agents in 
cancer patients, studies should not be limited to cell cultures, since tumour cells within the 
human body form associations with cells of other tissues and vary in terms of their distance from 
the nearest blood vessel. Cells in the center of a tumour are less exposed to nutrients, oxygen, 
and chemotherapy drugs than cells near the tumour surface.  In the context of ovarian cancer, 
solid tumours grow in a microenvironment 97 that also includes interactions with and exposure to 
stromal cells (fibroblasts, immune cells, and inflammatory cells), the tumour vasculature and 
extracellular matrix (ECM). Compared with normal tissues, tumours have a very different 
extracellular matrix, usually with an increased number of fibroblasts that synthesize growth 
factors, chemokines, and adhesion molecules. The diseased tumour stroma can enhance tumour 
cell expansion and malignant transformation and can reduce the sensitivity of tumour cells to 
drugs 98–101, which is not seen in vitro. Secondly, the higher “packing density” of tumour and 
stromal cells can hinder the access of drugs to some tumour cells 102, conferring resistance that's 
not seen in cell culture. Thirdly, the tumour vasculature and the blood flow will affect the solid 
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tumour microenvironment 103,104. The morphology of tumour blood vessels is also very different 
from that of normal tissues 104. These vessels contain excessive branching, loops and shunts, 
making blood flow unevenly distributed. The level of nutrients and oxygen can differ within 
areas of a solid tumour. Without sufficient levels of nutrients and oxygen, tumour cells have a 
lower proliferation rate, rendering them less sensitive to anti-cancer agents. A hypoxic tumour 
microenvironment can also lead to the activation of genes associated with angiogenesis and cell 
survival, and this effect is mediated by the transcription factor hypoxia inducible factor 1 (HIF-1) 
105,106. It is known that hypoxia often selects for cells deficient in DNA mismatch repair, which 
may help account for resistance to platinating agents in ovarian cancer in vivo 107,108. Lastly, the 
lymphatic system plays a role in the clearance of metabolites and wastes in the 
microenvironment 109. However, the shortage or absence of lymphatic vessel in solid tumours 
leads to interstitial hypertension in the tumour which impairs the penetration of macromolecules 
such as taxanes.  
 Platinating Agents and Their Mechanisms of Resistance in vitro and in vivo. 1.4
The mechanisms of resistance to platinum-based anti-cancer agents have been widely studied in 
cultured cells in vitro. Mechanisms involve enhanced DNA repair, decreased drug uptake, 
increased drug efflux and drug detoxification. The interruption of downstream apoptotic 
pathways has also been implicated in resistance to platinum agents. Firstly, since the target of 
platinating agents is double-stranded DNA, it is well-understood that a reduction in 
chemosensitivity may be associated with cellular responses to the DNA damage induced by these 
agents. Upon the formation of platinum-DNA adducts, cells can remove the adduct through 
DNA nuclear excision repair (NER) and base excision repair (BER) 110. Consistent with this 
view, cisplatin has been shown to be highly effective against testicular carcinoma when tumours 
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lack sufficient ability to repair platinum-damaged DNA structures 111. Moreover, the over-
expression of DNA polymerase β can promote resistance to tumour cell killing by platinating 
agents through its ability to promote repair of the DNA damage 112.  Transfection of cells with 
expression vectors containing cDNA that is coded for a DNA polymerase β cDNA have been 
shown to induce cisplatin resistance 113. Resistance to platinating agents can also arise when drug 
uptake or accumulation is decreased. Uptake of platinating agents in tumour cells depends 
mainly upon the activity of the cell surface copper transporter 1 (CTR1) 114.  CTR1 is able to 
actively transport copper ions and cisplatin into the cytoplasm and CTR1-deficient tumour cells 
demonstrate resistance to cisplatin 115. Cisplatin was shown to cause CTR1 internalization. This 
internalization results in reduced uptake of the drug and cisplatin resistance 116. Thirdly, an 
increase in efflux of platinating agents from cells or from the nucleus into the cytoplasm also 
accounts for reduction in drug efficacy.  For example, the copper-transporting P-type adenosine 
triphosphatases ATP7A and ATP7B were found to efflux both cisplatin and carboplatin from 
cells 117,118.  When an ATP7B cDNA expression vector was transfected into human epidermoid 
carcinoma KB-3-1 cells, the transfected cells were found to be resistant to both cisplatin (8.9-
fold) and copper (2.0-fold) 119.  Evidence of clinical relevance for ATP7B in tumour resistance to 
cisplatin in cancer patients was provided in a recent study showing that ATP7B overexpression 
is associated with poor outcome in cisplatin-treated patients with esophageal cancers and 
squamous cell cancers of head and neck 120,121.  
Upon platinating agents entering tumour cells, cellular glutathione can bind and inactivate the 
drugs. Glutathione (GSH) is a tri-peptide  (Glu-Cys-Gly) 122 that binds to platinating agents and 
serves as a co-factor to facilitate drug export from tumour cells, thereby conferring resistance to 
platinating agents 123,124. In addition, Glutathione-S-transferase (GST) augments platinating agent 
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resistance by catalyzing the formation of covalent bonds between GSH and platinating agents. 
GST gene amplification or GST immunostaining in tumoursand plasma correlated with cisplatin 
resistance in patients with cancers of the head and neck 125–127, suggesting that drug 
detoxification or transport by GSH and/or GST may play a role in clinical resistance to 
platinating agents. GSH can also confer resistance to cisplatin by enhancing DNA repair, or 
reducing cisplatin-induced oxidative stress 128. Lastly, cisplatin resistance has also been 
associated with blockage of drug-induced apoptosis through mechanisms such as mutations in 
p53 129 and decreased expression of the death receptor Fas 130.   The overexpression of the 
apoptotic inhibitors Bcl-2 or Bcl-XL overexpression has also been found to be associated with 
cisplatin resistance and reduced disease-free survival in ovarian cancer cell lines 131.  The 
apoptotic caspases 3 and 8 were also found to be downregulated in ovarian cancer cells 
exhibiting cisplatin resistance 132. Since tumour cells in patients are adjacent to stromal cells, the 
chemical components in interstitial fluid become very complex. Binding of drug to proteins in 
the interstitium can also contribute to resistance by binding cisplatin and reducing drug uptake 
into tumours 133. 
 Taxanes and Their Mechanisms of Resistance in vitro and in vivo. 1.5
In vitro studies have identified several mechanisms of resistance to taxanes. They are mainly 
associated with increased drug efflux by members of the ABC (ATP binding cassette) transporter 
family. Other mechanisms involve altered expression of tubulin subunits (or mutations in the 
genes coding for these subunits), as well as changes in the activity or expression of apoptotic 
regulatory proteins.  In vivo, the upregulation of taxane metabolizing agents from the cytochrome 
P450 family in liver was also observed to confer taxane resistance. 
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One or more members of the large family of ABC transporters exist on the membranes of all 
human cells. They function as efflux pumps that can transport structurally diverse, lipophilic 
compounds, including taxanes, out of the cell. The best known member of this family is P-gp (p-
glycoprotein, Abcb1) which is encoded by the ABCB1/MDR1 gene 134. The overexpression of 
Abcb1 in tumour cells leads to decreased accumulation of taxanes and, hence, drug resistance 135. 
Many in vitro studies have shown an inverse correlation of MDR1 gene expression with cellular 
sensitivity to paclitaxel, with confirmation of increased MDR1 mRNA and P-gp protein 
expression in paclitaxel-resistant cell lines 136,137. Another major mechanism of resistance to 
taxanes in vitro involves mutations in genes that code for tubulins, the binding targets for taxanes.  
Paclitaxel-resistant ovarian cancer cell lines showed point mutations in type I β-tubulin, which 
cause conformational changes in tubulins and the dynamics of microtubule polymerization 
/depolymerisation 138,139.  A unique mechanism of taxane resistance involves enzymes that are 
able to metabolize the drug and convert it into less toxic derivatives 140,141.  Enzymes from the 
cytochrome P450 family have been implicated in taxane resistance 142,143. A marked increase in 
resistance to docetaxel was observed in Chinese hamster ovary cells that expressed the CYP1B1 
gene in higher amounts than parental cells 142. A clinical study by McFadyen et al. 143 noted 
increased expression of CYP1B1 in primary and metastatic ovarian tumours, compared to normal 
ovary tissue.   
 Cell lines for in vitro study of ovarian cancer 1.6
When studying the function and mechanism of action of chemotherapeutic agents for ovarian 
cancer, cell lines are the most basic materials to start with. The ovary is made up of three 
different kinds of cells, each of which can develop into a different type of tumour, originating 
from epithelial cells, germ cells or stromal tissue 144.  Some ovarian malignancies can also be a 
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result of the metastasis of fallopian tube cancer 145. Among these different cancer cells from 
different origins, the most common type of ovarian cancer is epithelial in origin. Furthermore, 
epithelial ovarian cancer (EOC) can be divided into high-grade serous, low-grade serous, clear 
cell, endometrioid, and mucinous, each of which might have a different response rate in clinical 
settings 146. In this complicated context, biomarker identification and validation may be 
dependent upon the specific cell line(s) used in experiments. The parental A2780 human ovarian 
cancer cell line was derived from an ovarian cancer patient prior to chemotherapy treatment 147. 
Therefore, it is a chemotherapy-naïve cell line and has epithelial morphology 148. Approximately 
90% of all ovarian cancers develop from the epithelium of the ovary and thus the A2780 cell line 
is appropriate for the goals of this investigation 149. The parental cell line A2780 was used 
previously by our research group to generate a carboplatin-resistant A2780 cell line (A2780CBN) 
and a docetaxel-resistant cell line (A2780DXL) 150. 
 These cells grow as a monolayer in vitro as in epithelia but are likely of endometrioid subtype 
151. In addition to SK-OV-3, CaOV3, and OVCAR-3 cell lines, A2780 cells are widely used in 
the study of ovarian cancer in vitro 151.  Although A2780 cells have a deficiency in the DNA 
mismatch repair pathway,  have wild-type TP53, and other mutations uncharacteristic of High 
Grade Serous Ovarian Cancer (HGSOC) 148, they still have strong advantages because many 
mature models for the study of ovarian cancer were established using A2780 cells.  Moreover, its 
resistant sublines are very stable. 
 Study Design, Aims and Hypotheses 1.7
The treatment of ovarian cancer has been improving slowly in clinical settings. With the 
established effect of platinating agents, taxanes, and a combination of the two, the way the 
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regimen is administered becomes important. Previously, in vitro studies have established and 
characterized ovarian cell lines resistant to single agents (carboplatin or docetaxel) or to dual 
agents (namely carboplatin and docetaxel) 150. It was found that the above single agent resistant 
cell lines exhibited an inverse relationship between resistance to taxanes and resistance to 
platinum-based agents (and vice versa) 150,152,153, suggesting that there is little cross resistance 
between these agents in vitro. On the clinical side, longer time intervals between treatments have 
been shown to affect patient response to chemotherapy and alternating treatment with different 
drugs has shown promise in avoiding or overcoming resistance 154–158. Both these observations 
may indicate that genetic changes resulting in improved response to chemotherapy are time and 
dose dependent, as well as affected by the drug in use. Therefore, we planned an approach to 
study these effects in vitro using the single agent resistant cell lines, A2780CBN cells (resistant to 
carboplatin) and A2780DXL cells (resistant to docetaxel). By culturing the A2780CBN and 
A2780DXL cell lines in the absence of drug, we can investigate the ability of the resistance to 
persist over time and the changes in gene expression that may occur if primary resistance reverts 
to sensitivity. By culturing the A2780CBN cell line in increasing doses of docetaxel and the 
A2780DXL line in increasing doses of carboplatin, we can investigate the ability of a primary 
resistance to persist in the presence of another drug, allowing us to study how a primary 
resistance may change if exposed to an alternate drug. In addition, the development of resistance 
to the secondary drug may be studied.   We hypothesize that after sufficient exposure to one drug 
in this combination (until resistance is obtained), exposure to the other drug for several cycles of 
treatment may re-sensitize cells to the previously administered drug at a faster rate than simply 
leaving cells drug-free for an equivalent period of time.  In other words, exposure of carboplatin-
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resistant cells to docetaxel and selection for docetaxel resistance may result in re-establishment 
of carboplatin sensitivity and vice versa.  
In order to test this hypothesis, the objectives of this thesis were:  
Aim (1): to select carboplatin-resistant cells for resistance to docetaxel in vitro to generate 
A2780CBNDXL cells;  
Aim (2): to select docetaxel-resistant cells for resistance to carboplatin in vitro to generate 
A2780DXLCBN cells; and  
Aim (3): to assess the effect of new drug resistance on prior drug resistance.  
After patients have received chemotherapy treatment, they often receive no further 
chemotherapy treatment for an extended period of time.  This is called the “drug-free interval” 
and this may also play a role in restoration of chemotherapy sensitivity (as suggested in prior 
clinical studies).  Consistent with this view, it was found that the longer time interval between 
chemotherapy after recurrence of ovarian cancer, the better response is in later treatment 159. This 
evidence suggests that sensitivity to a previously administered drug may be restored by simply 
removing exposure to the drug. To assess the role of the drug-free interval on restoration of 
chemosensitivity, we also planned:  
Aim (4): to assess the effect of withdrawal of selection pressure for carboplatin-resistant cells 
(A2780CBNCC cells) on their sensitivity to paclitaxel and docetaxel, and  
Aim (5):  to assess the effect of withdrawal of selection pressure for docetaxel-resistant cells 
(A2780DXLCC cells) on their sensitivity to paclitaxel and docetaxel.  
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We thus further hypothesize that restoration of drug sensitivity will occur more rapidly upon 
selection/exposure to a new drug than by simply stopping exposure to the previously 
administered drug. 
It would also be helpful to identify changes in gene or protein expression that accompany 
restoration of sensitivity to the previously administered drug and acquisition of resistance to a 
new agent. This could provide significant insight into the mechanisms responsible for restoration 
of sensitivity to the previously administered drug and/or the mechanisms for acquisition of 
resistance to the new agent. By profiling gene expression in the above newly established cell 
lines and comparing with previous profiling studies, we also planned: 
Aim (6): to identify changes in gene expression associated with the loss and gain of drug 
resistance in the newly established cell lines.  
To further clarify our expectations, we hypothesize that in a comparison of the docetaxel-
resistant cell line that was previously carboplatin-resistant (A2780CBNDXL) with the carboplatin 
resistant cell line (A2780CBN), the gene expression changes will be associated with both the loss 
of carboplatin resistance and the gain of docetaxel resistance. The same would apply for the 
comparison between the carboplatin-resistant cell that was previously resistant to docetaxel 
(A2780DXLCBN) and the docetaxel resistant cell line (A2780DXL). Secondly, by comparing the 
cell line representing removal of A2780CBN cells from carboplatin selective pressure 
(A2780CBNCC) with the carboplatin-resistant cell line (A2780CBN), the resulting changes in gene 
expression may be associated with the loss of carboplatin resistance during the drug-free interval, 
if carboplatin resistance is lost. Similarly, by comparing the cell line representing removal of 
docetaxel selective pressure (A2780DXLCC) with the docetaxel resistant cell line (A2780DXL), the 
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changes in genes expression may be associated with loss of docetaxel resistance, if this 
phenotype is also lost. Thirdly, by studying the common and unique gene expression changes 
associated with the above comparisons, we should be able to identify common or unique genes, 
whose expression is altered upon restoration of drug sensitivity, whether it is by exposure to a 
new agent or by withdrawal of an existing agent. These gene profiling studies should provide us 
with important insight into possible mechanisms that could be exploited to restore 
chemosensitivity to chemoresistant tumours in ovarian cancer patients. 
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Chapter 2  
2. Materials and Methods 
 Cell Lines and Culture 2.1
The human A2780 ovarian carcinoma cell line was purchased from the European Collection of 
Authenticated Cell Cultures (ECACC, Salisbury, UK) and maintained in drug-free cell growth 
medium (RPMI-1640 with 2 mM glutamine supplemented with 10% FBS, 100 U penicillin, and 
0.1 mg/ mL streptomycin, all obtained from HyClone, South Logan, Utah, USA). The cells were 
incubated in 10 mL of the above medium in T75 flasks with vented cap (SARSTEDT, Montreal, 
QC). The flasks were placed in a humidified incubator at 37oC with 5% CO2. The cells were 
initially plated at a confluence of 30-40%. The medium was changed every 48 hrs until cells 
reached a confluence of 70-80%. When the cells reached confluence, subculturing was 
performed by adding 0.05% trypsin/EDTA solution (HyClone, South Logan, Utah, US) to the 
cells. Chemoresistant A2780CBN and A2780DXL cell lines were provided by Dr. Carita Lanner of 
the Northern Ontario School of Medicine (Sudbury, Canada).  The resistance to carboplatin in 
the A2780CBN cell line was maintained by adding 22.2 µM of the drug in RPMI-1640 with 2 mM 
glutamine, 10% FBS and penicillin/streptomycin. Likewise, the resistance to docetaxel in the 
A2780DXL cell line was maintained by adding 0.405 µM docetaxel in RPMI-1640 with 2 mM 
glutamine, 10% FBS and 1% penicillin/streptomycin. The resistance to docetaxel in a cell line 
where A2780CBN cells were selected for resistance to docetaxel (A2780CBN→DXL cells ) was 
maintained by adding 1.09 nM docetaxel in RPMI-1640 with 2 mM glutamine, 10% FBS and 
penicillin/streptomycin. The resistance to carboplatin in a cell line where A2780DXL cells were 
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selected for resistance to carboplatin (A2780DXL→CBN cells) was maintained by adding 8.20 µM 
carboplatin in RPMI-1640 with 2 mM glutamine, 10% FBS and penicillin/streptomycin. The 
medium containing drug was changed every 48 hrs. 
 Cell Line Selection 2.2
A2780CBN→DXL cells were generated from A2780CBN cells through selection in increasing 
concentrations of docetaxel. The selection started at 1.0 pM docetaxel, which is about 350-fold 
below the average IC50 value for docetaxel in A2780CBN cells (0.36 nM ± 0.31 pM) 150 and was 
denoted as Selection Dose 1 (S1).  Similarly, A2780DXL→CBN cells were generated using 
A2780DXL cells, through selection in increasing concentrations of carboplatin with an S1 dose of 
1.0 nM carboplatin, which is about 2200-fold below the average IC50 value for carboplatin in 
A2780DXL cells (2.20 µM ± 0.33µM)150.  
The starting dose of carboplatin (1.0 nM) is higher than that of docetaxel (1.0 p M), because in 
previous experiments by Armstrong, et al 150, the IC50 of carboplatin in A2780DXL cells are 
higher than that of docetaxel in A2780CBN cell, meaning carboplatin is less toxic to cells than 
docetaxel.  
Fresh medium containing drug at S1 was replaced every 48 hrs. When confluence reached 70-
80%, the cells would undergo sub-culturing. Twenty four hrs after sub-culturing, the medium 
containing the same dose of respective drug was added to the cells. After reaching 70-80% 
confluence, the cells were trypsinized and lifted from the bottom of the flask. Aliquots of the 
cells for cryostorage were maintained at a density of approximately 1 million cells/ mL in a 
medium that contained 20% FBS and 5%-10% DMSO. They were transferred to 1mL cryovials 
and stored in liquid nitrogen. The rest of the cells were re-plated in new flasks. After 24 hrs to 
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allow cells to attach to the bottom of the flask, medium containing higher concentrations of drug 
was added to various flasks of the cells. These had drug concentrations 1.25-fold, 1.5-fold, or 3-
fold higher than S1. Cells surviving in the highest of these drug concentrations were transferred 
into new flasks and aliquots were stored in liquid nitrogen.  The highest concentration of drug in 
which cells survived was denoted as Selection Dose 2 (S2). This entire selection procedure was 
repeated until A2780CBN→DXL cells reached S8 and A2780DXL→CBN cells reached S10 since cells 
could not survive in the dose. A co-cultured control (CC) cell line was also prepared 
(A2780CBN→CC cells) by culturing A2780CBN cells in the absence of docetaxel for the same 
number of passages as the A2780CBN→DXL cell line in the same incubator as the drug-selected 
cells.  These were also stored in liquid nitrogen.  Similarly, co-cultured A2780DXL→CC cells were 
generated by culturing A2780DXL cells in the absence of carboplatin for the same number of 
passages as the A2780DXL→CBN cell line.  The chemotherapy naïve A2780 cell line was cultured 
in drug free medium (A2780CC cells) as a control for changes in drug sensitivity or gene 
expression due to multiple passages of continuous cell culture.  
 Cell Viability Test  2.3
 Preparation of Methylcellulose 2.3.1
In order to suspend the cells in a medium that allows them to form countable colonies in 3 
dimensions, a solution of methylcellulose was used. An Erlenmeyer flask containing a magnetic 
stirring bar was autoclaved on a minimum 20 min gravity cycle and then weighed. Four hundred 
and sixty (460) mL of sterile Baxter water was added to the flask and brought to a boil. Fifteen 
grams of methylcellulose powder (Sigma Aldrich, St Louis MO USA) was added to the flask 
which was shaken vigorously for 7-8 min to evenly suspend the powder. Subsequently, a volume 
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of 500 mL of Iscove’s Modified Dulbecco’s Medium (IMDM) with 1% penicillin/streptomycin 
(HyClone, South Logan, Utah, US) was added to the methylcellulose mixture in a tissue culture 
hood. The mixture was stirred at 4°C overnight and became clear and extremely viscous. On the 
second day, 70 mL aliquots of the uniform methylcellulose solution were placed into 100 mL of 
sterile urine specimen cups and were frozen at -20°C.  
 Clonogenic Assays 2.3.2
A2780CBN→DXL, A2780DXLCBN, A2780CBNCC, A2780DXLCC, A2780CBN, A2780DXL, A2780CC 
were assessed for their sensitivity to either carboplatin or docetaxel using standard clonogenic 
assays. Each of the cell lines was allowed to reach 70-80% confluence. Then the cells were lifted 
from a T75 flask by trypsin/EDTA treatment and plated in 12 T25 flasks with each flask 
containing the same number of cells (0.2 x 106 cells per flask). The cells were placed in 5 mL of 
drug-free RPMI-1640 medium containing 2 mM glutamine, 10% FBS and 1% 
penicillin/streptomycin. After 24 hrs, the medium was removed from each flask and replaced 
with fresh medium containing different concentrations of docetaxel or carboplatin. The 12 flasks 
were numbered 1 to 12, with 1 containing the highest concentration of the drug and 12 lowest as 
no-drug control (docetaxel doses 1 to 11: 100 M, 0.1 M, 10 nM, 3 nM, nM, 0.3 nM, 0.1 nM, 
30 pM, 10 pM,  1 pM, 0.1pM. Carboplatin doses 1 to 11: 1 mM, 0.1 mM, 30 M, 10 M, 3 M, 
1 M, 0.3 M, 0.1 M, 30 nM, 10 nM, 1 nM). After 24 hrs, 30 mL of FBS were added to a 
thawed, stored 70 mL aliquot of methylcellulose and the sample shaken vigorously until the 
mixture became uniform. After allowing the bubbles to vent by gravity, 2.7 mL aliquots of the 
methylcellulose mixture were placed into 13 mL Rohre tubes. After 24 hrs of incubation in the 
absence or presence of drug, the medium in the T25 flasks was removed and transferred to 
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individual 15 mL tubes. The cells in each T25 flask were released with 1 mL of trypsin/EDTA 
solution and transferred to the correspondingly labeled tube. Each flask was washed once with 2 
mL of PBS (HyClone, South Logan, Utah, USA) to ensure all viable cells were collected. The 
cells were centrifuged at 1000 rpm for 8 min. The supernatant was discarded and 300 L fresh 
medium was added to suspend the cell pellet. The whole suspension was pipetted into 
corresponding labeled Rohre tubes containing 2.7 mL of methylcellulose solution. The mixtures 
containing cells were vortexed thoroughly to ensure even distribution of this cell-methylcellulose 
suspension, 1.2 ml were placed into one correspondingly labeled well in a 6-well plate (2 x 6 
well plates per clonogenic assay). Each well was numbered 1-12 to represent the 12 drug 
concentrations. The plates were incubated at 37oC with 5% CO2 for 5-7 days until large colonies 
(>50 cells) were formed and could be counted. 
 Survival Curves and Average of IC50 2.3.3
After colony formation, the mean number of colonies present in five random microscopic fields 
was determined for each well (magnification 10x10). Pictures of five random fields (x 10) were 
taken for manual counting later. The mean number of colonies at a particular drug concentration 
was divided by the mean number of colonies for the no-drug control to determine the survival 
fraction. The data were entered into Graph Pad Prism software (Graph Pad Software Inc, La 
Jolla, CA). The survival fraction was plotted against the log of drug concentration (M). The 
survival analysis curve log [inhibitor] vs. normalized response – variable slope was used to fit 
the data and calculate the IC50, where the log [inhibitor] represented the log of the drug 
concentration, the normalized response represented the survival fraction, and the variable slope 
allowed for the calculated curve to best fit the data. The drug concentration at which the numbers 
of colonies was 50% of the no drug control was then computed as the IC50 value.  
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 Statistical Determination of IC50 Significance  2.3.4
Each experiment was performed three times. Statistical analyses were performed to evaluate the 
significance of differences in IC50 values between different cell lines. A Student’s T Test with 
two-tailed distribution and two-sample equal variance was used as the test for significance. A p 
value of <0.05 indicates a significant difference between the values of two sets of data.   
 Microarray Analysis 2.4
 RNA Isolation 2.4.1
In order to assess gene expression differences between the cell lines, RNA must be isolated from 
the various cell lines and its quantity and quality assessed. Total RNA was purified from 
A2780CBNDXL, A2780DXLCBN, A2780CBNCC, A2780DXLCC, A2780CBN, A2780DXL, and 
A2780CC cells using Qiagen RNeasyTM Mini Kits (Mississauga, ON, Canada). An amount of 0.5 
x 106 cells was plated in each of three 3 cm plates with 5mL growth medium. After 24 hr 
incubation, the cell-culture medium was completely aspirated and the cells washed by adding 
500 µL PBS. Subsequently, 350 µL lysis buffer RLT (denaturing guanidine-thiocyanate buffer) 
was added to the monolayer of cells, and after 1 minute, the lysate was scraped down and 
pipetted into a 2 mL tube. The lysate was passed 5 times through a 20-gauge needle with a 1 mL 
syringe, after which 350 mL of anhydrous alcohol was added, with the mixture being pipetted up 
and down several times. Each sample was then loaded onto an RNeasy spin column and placed 
into a 2 mL collection tube. The sample was then centrifuged at 10,000 rpm for 30 s to bind the 
RNA to the spin column. After discarding the flow-through, 700 mL of buffer RW1 was added 
to each column and then the whole assembly was centrifuged again at 10,000 rpm for 30 s. After 
discarding the flow-through, 700 µL of buffer RPE was added to each column and the 
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centrifugation repeated. Another 700 µL buffer RPE was added and the process repeated again. 
The column was placed into a 1.5 mL sterile collection tube and 50 µL of RNase-free water was 
added to the membrane in the column to elute bound RNA. The sample was then centrifuged at 
full speed (14,000 rpm) for 1 min. The eluate was pipetted back on to the column and the process 
repeated again to ensure complete RNA elution. Aliquots of 5 µL RNA sample were transferred 
to another sterile tube. The tubes containing RNA samples were stored in -80°C freezer for 
further use. 
 Quantity and Integrity of Total RNA 2.4.2
Sufficient quantity and integrity of RNA are essential for microarray analysis and these were 
assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA, USA). 
One µl of each RNA sample was loaded onto RNA Nano chips after chip priming (Caliper 
Technologies, Hopkinton, MA, USA). The Agilent bioanalyzer generated a gel-like image of 
each total RNA preparation, determined the RNA concentration, and quantified RNA integrity as 
an RNA Integrity Number (RIN). The RIN can range from 1 to 10, where 1 represents totally 
degraded RNA and 10 is highly intact RNA. The RIN value was calculated by the Agilent 
Bioanalyzer using a specific algorithm. RIN values of 6.0 or higher were considered of sufficient 
quality for microarray experiments. Since three RNA samples were prepared per cell line, the 
quantity and quality of each preparation was determined by running RNA Nano chips on the 
Bioanalyzer.  If all samples met the RNA quality standards, a master solution with an RNA 
concentration of approximately 100 ng/uL was prepared using all three samples.  The master 
solution was then assessed using the Agilent 2100 Bioanalyzer in order to accurately determine 
final RNA concentrations and RNA quality. 
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 Preparation of cRNA 2.4.3
After confirmation of sufficient RNA quantity and quality, microarray analysis proceeded, 
starting with the preparation of cRNA (complementary RNA) using the Agilent Quick Amp 
Labeling Kit (Santa Clara, CA, USA). Array comparisons included A2780CBNDXL vs. A2780CBN, 
A2780DXLCBN vs. A2780DXL, A2780CBNCC vs. A2780CC, and A2780DXLCC vs. A2780CC. 
Consequently, RNA was isolated from each of the above cell lines to facilitate these comparisons.  
Cell lines under comparison were at a similar passage number. To begin array hybridization 
experiments, Spike A and Spike B solutions were prepared as described by the manufacturer 
(http://www.agilent.com/cs/library/usermanuals/Public/G4140-90050_GeneExpression 
_TwoColor_6.9.pdf) 160, where these solutions contained RNA transcripts that anneal to 
complementary probes on the microarray but not to complementary sequences on the array that 
represent genes from the human genome. The solutions were used to “spike” the RNA solutions 
from the cell lines described above, which were first diluted to a concentration of 500 ng RNA in 
8.3 µL of sterile distilled water.  To the RNA solutions was added 2 µL of Spike A (or Spike B) 
solution and 1.2 µL T7 Promoter Primer solution. The mixture containing primer and templates 
was denatured at 65°C, after which a dNTP mixture, DTT, First Strand Buffer, MMLV-RT and 
RNaseOut were added, as instructed and provided by the manufacturer (Agilent Technologies).    
By incubating this sample mix at 40°C for 2 hrs and then at 65°C for 15 minutes, cDNA 
preparations were generated and denatured. In the next step, T7 RNA polymerase was used to 
generate RNA transcripts of the cDNA (cRNA).  During transcription either Cyanine 3-CTP 
(Cy3, red solution, green fluorescence) or Cyanine 5-CTP (Cy5, blue solution, red fluorescence) 
were incorporated into the cRNA. Thus, two sets of probes were prepared for array 
hybridization: one Cy3-labelled cRNA from one cell line and one Cy5-labelled cRNA from the 
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other cell line.  These were then used for comparative assessment of gene expression by array 
hybridization.  In some experiments, the Cy3 and Cy5 dyes were used to label the opposite 
cRNA preparation in order to control for differences in dye stability or efficiencies in labeling.  
The reaction mixture was then incubated at 40°C for 2 hours to allow transcription of the cRNAs. 
Since the 2nd strand cDNA and other reaction components were still present in the mixture, 
cRNA samples were purified by binding and elution from a Qiagen RNeasy mini spin column. 
Accordingly, 350 µL of Buffer RLT and 250 µL anhydrous ethanol were added to each cRNA 
preparation. After thorough mixing, the solution was transferred to a spin column placed in a 2 
mL collection tube and centrifuged at 13,000 rpm for 30 s at room temperature. Then, 500µL of 
Buffer RPE was added to the spin column twice to wash the cRNA and the washes discarded by 
centrifugation at 13,000 rpm for 30 s at room temperature.  To elute the cRNA, 30 µL of RNase-
free water was added directly to the column and the column centrifuged at full speed for 30 
seconds at 4ºC. The eluate contained the purified cRNA and was kept on ice. The cRNA was 
quantified using a NanoDrop ND-1000 UV-VIS Spectrophotometer version 3.2.1 (Agilent 
Technologies).  The RNA 260nm/280nm absorbance ratio was recorded as a measurement of 
RNA purity. An A260/280 ratio of 1.9-2.1 was considered of sufficient purity for microarray 
analysis. cRNA concentrations (in ng/µL) were measured and used to determine the cRNA yield. 
A volume that contained 825 ng of cRNA was used for array hybridization, as described below. 
Cy 3 or Cy5 dye concentrations (pmol/µL) were also recorded to determine the efficiency of dye 
labelling. Dye labelling efficiency equal to 8.0 pmol of dye/µL of cRNA (or greater) was 
considered sufficient for array hybridization.   
 Array Hybridization 2.4.4
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The labelled and purified cRNAs were loaded onto 4x44K microarrays (Agilent Technologies) 
containing oligonucleotides that represent probes for almost the entire human genome. Two 
identical tubes were prepared, one containing Cy3-labelled cRNA from the first cell line in the 
comparison and the other containing Cy5-labelled cRNA from the second cell line. Meanwhile, 
two other tubes were prepared, where one contained Cy5-labelled cRNA from the first cell line 
and Cy3 labelled cRNA from the second cell line. The four tubes were incubated in 
fragmentation buffer at 60 ºC for 30 min to fragment the cRNA to increase hybridization 
efficiency to the oligomer nucleotides on the array.  2x Gex Hybridization Buffer was added to 
stop the fragmentation and the solutions mixed well without introducing bubbles. The samples 
were centrifuged at full speed (14,000rpm) for 1 min to drive all the solution off the tube walls 
and lid. A volume of 100 µL of each mixed sample was loaded into one of the four chambers on 
a clean array slide. cRNA labelled with C3 dye and cRNA labelled with the Cy5 dye were 
hybridized to two microarrays, while the reverse-labelled samples were hybridized to the 
remaining two microarrays to control for differences in dye incorporation or dye quenching 
between the samples.  The slides were placed in a rotisserie within a hybridization oven at 65°C 
for 17 hrs of hybridization.   
 Microarray Wash 2.4.5
After hybridization, the slides were immersed and washed in 100% acetonitrile in a staining dish 
for 5 min. The procedure was repeated once and then acetonitrile was replaced with Milli-Q 
water for 5 additional washings. The slides were then placed in sufficient Gene Expression Wash 
Buffer 1 and then Gene Expression Wash Buffer 2 (Agilent Biotechnologies) to avoid ozone-
related problems in array scanning. 
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 Array Scanning and “Between-Array” Comparisons 2.4.6
A Gene Pix 4000A Scanner (Agilent Technologies) was used to scan the hybridized and washed 
array slides. Agilent Feature Extraction software version 9.5.3 (Agilent Technologies, USA) was 
used to extract gene expression data from the arrays. We extracted genes that exhibited an 
expression change over 2 fold (upregulated: ≥ 2 fold change, downregulated ≤ -2 fold changes) 
and at the same time, p was less than 0.05. 
The profile of gene expression changes of the following four cell line pairs were directly 
compared “in array” because the paired samples were loaded on the same chip and the 
microarray result is “relative” data as a result of comparison: 
A2780CBNDXL vs. A2780CBN    A2780DXLCBN vs. A2780DXL 
A2780CBNCC vs. A2780CC          A2780DXLCC vs. A2780CC 
By extracting absolute array data of each cell line in each pair, we were also able to compare 
gene expression between cell lines that were not loaded and compared directly on array chips.  
This enabled comparisons in gene expression between the following cell line combinations:    
A2780CBNDXL vs. A2780DXL   A2780DXLCBN vs. A2780CBN  




 Identification of Important Changes in Gene Expression 2.4.7
To determine the statistical significance of differences in gene expression changes between the 
various cell line pairs, SAS software (Statistic analytical software, SAS Institute, US) was used. 
Common gene expression changes between two sets of comparison and distinct gene expression 
changes solely in one set of cell lines were noted. For example, certain gene expression changes 
that happen in A2780CBNDXL vs. A2780CBN were also found in A2780CBNCC vs. A2780CBN.  On 
the other hand, it is also of importance to show unique gene expression changes found in 
A2780CBNDXL vs. A2780CBN but not expressed in A2780CBNCC vs. A2780CBN, and vice versa. 
These comparisons enable differentiation between changes in gene expression due to loss of 
selection pressure (A2780CBNCC vs. A2780CBN) and changes in gene expression due to 
acquisition of a new drug-resistant phenotype (A2780CBNDXL vs. A2780CBN).  
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Chapter 3  
3. Results 
  Cell Line Selection and Characterization 3.1
 Generation of A2780CBNDXL, A2780DXLCBN, A2780CBNCC, A2780DXLCC  cell lines 3.1.1
Four new cell lines were established: a carboplatin-resistant cell line that was selected for 
resistance to docetaxel (A2780CBNDXL cells), a docetaxel-resistant cell line that was selected for 
resistance to carboplatin (A2780DXLCBN cells), a carboplatin-resistant cell line that was 
propagated for the same period of time in the absence of any drug (A2780CBNCC cells), and a 
docetaxel-resistant cell line that was propagated for the same period of time in the absence of 
drug (A2780DXLCC cells). Multiple clonogenic assays were used to test their sensitivity to either 
carboplatin or docetaxel or both. In this study, A2780CBNDXL cells, a subline of A2780CBN cells 
selected for resistance to docetaxel, was generated by treating A2780CBN cells with increasing 
concentrations of docetaxel. The highest surviving selection dose 8 was 1.09 nM docetaxel after 
25 passages (Table 3.1). Likewise, by treating A2780DXL cells with ascending doses of 
carboplatin, we generated a subline of A2780DXL cells, which was selected for resistance to 
carboplatin (A2780DXLCBN cells). The cell line reached its maximal selection dose at 8.2 M 
carboplatin after 29 passages (Table 3.2).  
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Table 3.1 A2780CBNDXL selection dose concentrations 
*MTD=maximally tolerated dose 
  
Dose number Treatment dose  (docetaxel)     Fold above previous dose  
1 1.0 pM  N/A 
2 3.0 pM 3.0 
3 9.0 pM 3.0 
4 27 pM 3.0 
5 81 pM  3.0 
6 0.24 nM  3.0 
7 73 nM  3.0 




Table 3.2  A2780DXLCBN selection dose concentrations 
*MTD=maximally tolerated dose 
  
Dose number Treatment dose  (carboplatin)     Fold above previous dose  
1 1.0 nM  N/A 
2 3.0 nM 3.0 
3 9.0 nM 3.0 
4 27 nM 3.0 
5 81 nM  3.0 














We also generated A2780CBNCC and A2780DXLCC cells by growing A2780CBN and A2780DXL in 
drug-free medium, respectively, for the same number of passages as the above drug-selected 
cells.   As was mentioned earlier, the establishment of A2780CBNCC or A2780DXLCC cells was, 
firstly, to mimic the drug free interval in the clinical setting. Secondly, these cell lines can serve 
as a control to determine whether any of the properties of  the A2780CBNDXL and A2780DXLCBN 
cell lines are simply due to removal of carboplatin and docetaxel selection pressure, respectively. 
Photomicrographs of the resistant sub lines, and their co-cultured control counterparts at similar 
passage were taken. Comparing the morphology of the new cell lines with those used in the 
beginning to generate them (Figure 3.1), there appear to be no obvious morphology changes, 
compared to the original cell lines respectively, in the A2780CBNDXL, A2780CBNCC, and 
A2780DXLCC cell lines. However, the A2780DXLCBN subline exhibits a very different 
morphology from that of A2780DXL cells. These cells were more spindle shaped at the final 
selection dose (Figure 3.1). This might be a consequence of carboplatin resistance 
establishmentin A2780DXL cells.  However, the A2780CBN cells are not spindled shaped, 
suggesting that there are clear differences between A2780DXLCBN and A2780CBN cells, despite 





Figure 3.1 Photomicrographs of all resistant cell lines at their final selection doses. 
Photomicrographs comparing the cell morphology of the resistant sub cell lines A2780CBNDXL, 
A2780DXLCBN, their co-cultured controls A2780CBNCC, A2780DXLCC, single agent resistant 
cell lines A2780CBN, A2780DXL and parental cell line A2780CC at similar passage numbers. 




 Characterization of A2780CBNDXL Cells 3.1.2
To assess the sensitivity of A2780, A2780CBN, A2780DXL, and A2780CBN→DXL cells to docetaxel 
(Figure 3.2, Table 3.3), these cell lines were incubated with various concentrations of docetaxel 
ranging from 0.1 pM to 10 M. The concentration of docetaxel at which colony formation for 
A2780CBN→DXL cells [S8 (selection dose number 8), P25 (passage number 25)] in a clonogenic 
assay was suppressed by 50% (IC50) was then determined to be 56  ± 9.3 n M, which was 76-fold 
higher than the IC50 for docetaxel in A2780CBN (P1) cells (0.74  ± 0.20 nM, p=0.008). The IC50 
for docetaxel, however, was 4.2-fold lower than that of A2780DXL (P1) cells (239 ± 59 nM 
docetaxel p=0.05). This suggests that docetaxel resistance is established in the A2780CBNDXL 
cell line, but not to the extent seen in A2780DXL cells. While A2780DXL cells were significantly 
more resistant to docetaxel compared to A2780CBN cells (p=0.005) and A2780 cells (p=0.015), 
the IC50 of A2780CBN cells to docetaxel was not significantly different from that of A2780 cells 
(p=0.44). In summary, A2780CBNDXL cells exhibited 76 times more resistance to docetaxel than 
A2780CBN cells, but were 4 times less resistant to docetaxel than A2780DXL cells. 
Subsequently, the sensitivity of A2780CBNDXL cells to carboplatin was assessed and compared to 
that of A2780CBN cells and A2780 cells. (Figure 3.3, Table 3.4). This allowed us to test if prior 
carboplatin resistance is affected by selection for docetaxel resistance. The cells were treated 
with carboplatin concentrations ranging from 0.1 nM to 1 mM.  The IC50 of A2780CBNDXL cells 
for carboplatin was determined to be 18 ± 6.8 M.  This was not significantly different from the 
IC50 of A2780CBN cells (63 ± 25 M carboplatin, resistance factor 3.4 fold; p=0.19). 
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Therefore, the results above indicated that the resistance to docetaxel could be established in 
A2780CBN cells to obtain an A2780CBNDXL cell line. Moreover, the original resistance to 




Figure 3.2 Sensitivity of A2780CBNDXL, A2780CBN, A2780DXL, and A2780CC cells to 
docetaxel, as measured in a clonogenic assay 
Dose-response curve showing the relationship of the log of docetaxel concentrations in molarity 
(M) to the survival fraction of A2780CBNDXL (P25, S8), A2780CBN (P0), A2780DXL (P0), and 
A2780CC (P0) colonies in varying concentrations of docetaxel. The IC50’s listed are the mean ± 
SEM of 3 independent experiments. 
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Table 3.3 Comparisons of IC50’s to docetaxel among cell lines A2780CBNDXL, A2780DXL, 











IC50 (nM) 56 239 0.74 0.49 
S.E.M (nM) 9.3 59 0.19 0.22 (1)  
p to A2780DXL 0.05*    
p to A2780CBN 0.008** 0.005*   
p to A2780 0.004** 0.015* 0.44  
Fold change to 
A2780DXL  
0.23    
Fold change to 
A2780CBN 
76 323   
Fold change to 
A2780 
115 488 1.5  
* Significance of difference (p<0.05) 




Figure 3.3 A2780CBNDXL, A2780CBN, A2780CC treated with carboplatin 
Dose-response curve showing the relationship of the log of carboplatin concentrations in 
molarity (M) to the survival fraction of A2780CBNDXL (P25, S8), A2780CBN (P0) and A2780CC 
(P0) colonies exposed to varying concentrations of carboplatin. The IC50’s listed are the mean ± 
SEM of 3 independent experiments.   
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Table 3.4 Comparisons of IC50’s for carboplatin among A2780CBNDXL, A2780CBN, A2780 
cell lines 
Cell lines 






IC50 (µM)  18 63 3.8 
SEM (µM) 6.8 25 1.8 
P to A2780CBN 0.19   
p to A2780 0.03* 0.03*  
Fold change to 
A2780CBN 
0.29   
Fold change to 
A2780 
4.8 16.5  
* Significance of difference (p<0.05) 
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 Characterization of A2780DXLCBN Cells 3.1.3
To determine the effect of selection for carboplatin resistance on prior resistance to docetaxel, a 
series of clonogenic assays on selected cell lines was performed. To meet this objective, the 
sensitivity to carboplatin was assessed in the following cells lines: A2780DXLCBN, A2780DXL, 
A2780CBN, and parental A2780 cells. Carboplatin concentrations ranged from 0.1 nM to 1 mM.  
The IC50 of A2780DXLCBN cells to carboplatin was determined to be 40 ± 2.9 
 M, which was 
significantly higher than that of A2780DXL cells (1.7 ± 0.79  M carboplatin, resistance factor 24 
fold, p=0.0002). However, there was no significant difference (p=0.47) in carboplatin sensitivity 
between A2780DXLCBN cells (40 ± 2.9 M carboplatin) and A2780CBN cells (63 ± 2.5 M 
carboplatin, resistance factor 0.6 fold) (Figure 3.4, Table 3.5).  
Next, the sensitivity of A2780DXLCBN cells to docetaxel was assessed and compared with that of 
A2780DXL cells and A2780 cells. The cells were treated with docetaxel concentrations ranging 
from 0.1 pM to 10 µM. The IC50 of A2780DXLCBN cells for docetaxel was determined to be 1.8 
± 0.81 nM docetaxel, which was significantly lower than that of the original A2780DXL cell line 
(238 ± 58 nM docetaxel, resistance factor 135- fold, p=0.016). However, there was no significant 
difference (p=0.2) in the IC50 to docetaxel between A2780DXLCBN cells (1.8
   ± 0.081 nM) and 
parental A2780 cells (0.49 ± 0.22 nM) (Figure 3.5, Table 3.6).  
Our results thus showed that A2780DXL cells can acquire carboplatin resistance, and that the 




Figure 3.4 A2780DXLCBN, A2780DXL, A2780CBN, A2780CC treated with carboplatin 
Dose-response curve showing the relationship between the log of carboplatin concentrations in 
molarity (M) and the survival fraction of A2780DXLCBN (P29, S10), A2780DXL (P0), A2780CBN 
(P0) and A2780CC (P0) colonies exposed to varying concentrations of carboplatin. The IC50s 
listed are the mean ± SEM of 3 independent experiments.   
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Table 3.5 Comparisons of IC50’s for carboplatin among A2780DXLCBN, A2780DXL, 
A2780CBN, A2780 cell lines 
Cell lines 
A2780DXLCBN 








IC50 (µM) 40 63 1.6 3.8 
S.E.M (µM) 2.9 2.5 0.79 1.2 
p to A2780CBN 0.47    
p to A2780DXL 0.0002*** 0.09   
p to A2780 <0.0001**** 0.02* 0.25  
Fold change to 
A2780CBN 
0.6    
Fold change to 
A2780DXL 
24 38   
Fold change to 
A2780 
10 16   
* Significance of difference (p<0.05) 
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Figure 3.5 A2780DXLCBN, A2780DXL, A2780CC treated with docetaxel  
Dose-response curve comparing log of docetaxel concentrations in molarity (M) to the survival 
fraction of A2780DXLCBN (P29, S10), A2780DXL (P0) and A2780CC (P0) colonies exposed to 
varying concentrations of docetaxel. The IC50s listed are the mean ± SEM of 3 independent 




Table 3.6 Comparisons of IC50’s for docetaxel among A2780DXLCBN, A2780DXL, A2780 cell 
lines 
Cell lines 
A2780DXLCBN       






IC50 (nM) 1.8  238 0.49 
SEM (nM) 0.81 58 0.22 
p to A2780DXL 0.016*   
p to A2780 0.2 0.015*  
Fold change to 
A2780DXL 
0.007   
Fold change to 
A2780 
3.6   
* Significance of difference 
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 Characterization of A2780CBNCC Cells 3.1.4
The A2780CBNCC cell line was established to determine the effect of carboplatin withdrawal on 
the phenotype of A2780CBN cells.  This would also mimic the drug-free interval in terms of 
withdrawal from carboplatin in ovarian cancer patients in the clinical setting. The A2780CBNCC 
cells were cultured in drug-free medium until they reached a passage number equal to 
A2780CBNDXL cells (P25). Sensitivity of A2780CBNCC cells to carboplatin was compared with 
A2780CBN cells and A2780 cells. The cells were treated with carboplatin ranging from 0.1 nM to 
1 mM in concentration. The IC50 of A2780CBNCC cells was 18 ± 5.0 M carboplatin, while for 
A2780CBN cells it was 63 ± 25 M carboplatin.  This suggested that there was no significant 
change in the degree of resistance when comparing A2780CBNCC cells to the original A2780CBN 
parental cells (p=0.18) (Figure 3.6, Table 3.7). Therefore, resistance to carboplatin was not 












Figure 3.6 A2780CBNCC, A2780CBN, A2780CC cells treated with carboplatin 
Dose-response curve showing the relationship between the log of carboplatin concentrations in 
molarity (M) to the survival fraction of A2780CBNCC (P0), A2780CBN (P0) and A2780CC (P0) 
colonies exposed to varying concentrations of carboplatin. The IC50’s listed are the mean ± SEM 




Table 3.7 Comparisons of IC50’s for carboplatin among A2780CBNCC, A2780CBN, and 








IC50 (µM) 18 63 3.8 
S.E.M (µM) 5.0 25 1.2 
p to A2780CBN 0.18   
p to A2780 0.013* 0.03*  
Fold change to 
A2780CBN 
0.27   
Fold change to A2780 4.6   
* Significance of difference 
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 Characterization of A2780DXLCC Cells 3.1.5
Likewise, the A2780DXLCC cell line was created to determine the effect of docetaxel withdrawal 
on the phenotype of A2780DXL cells.  This would also represent the clinical situation of docetaxel 
withdrawal after chemotherapy in ovarian cancer patients.  The sensitivity of A2780DXLCC cells 
to docetaxel was compared to that of parental A2780DXL cells using clonogenic assays. The cells 
were treated with docetaxel concentrations ranging from 0.1 pM to 10 M. The IC50 of 
A2780DXLCC cells for docetaxel was determined to be 50 ± 0.30 nM docetaxel. This was a 
significant reduction in docetaxel resistance when compared to parental A2780DXL cells (239 ± 
59 nM docetaxel, p=0.03, 5-fold increase in drug sensitivity). Despite the reduction in docetaxel 
resistance, docetaxel sensitivity was not restored to that of A2780 parental cells (0.50 ± 0.22 nM 
docetaxel, p<0.0001, 102-fold greater sensitivity) (Figure 3.7, Table 3.8). Therefore, the results 














Figure 3.7 A2780DXLCC, A2780DXL, A2780CC treated with docetaxel 
Dose-response curve comparing log of carboplatin concentrations in molarity (M) to the survival 
fraction of A2780DXLCC (P29), A2780DXL (P0) and A2780CC (P0) colonies exposed to varying 













IC50 (nM)  50 239 0.5 
S.E.M (nM) 0.3 59 0.22 
p to A2780DXL  0.03*   
p to A2780  <0.0001**** 0.02*  
Fold change to 
A2780DXL 
0.21   
Fold change to 
A2780 
102 486  
* Significance of difference 
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 Gene profile analysis 3.2
In this study, microarray experiments involving the hybridization of labeled RNA samples to a 
very large set of oligonucleotide probes (almost the full human genome) were conducted to 
detect differences in gene expression between several pairs of the above cell lines. Gene 
expression differences were then expressed as fold-changes, where positive numbers represented 
elevated gene expression and negative numbers represented reduced gene expression.  Likely, 
both drug withdrawal and selection for resistance to a new anti-cancer drug precipitated the 
observed positive and negative changes in gene expression. 
 Comparison of Gene Expression between A2780CBNDXL and A2780CBN Cells 3.2.1
A2780CBNDXL (P25, S8) and A2780CBN (P1) cells were cultured in drug-free medium for 48 
hours, after which total RNA was extracted from both cell lines. All RNA preparations with RIN 
values between 9.0 and 10.0 were deemed suitable for microarray analysis. Upon completion of 
the microarray experiments, we noted all genes whose expression wassignificantly different (p ≤ 
0.05) by ≥2-fold between the Cy-3 labelled and Cy-5 labelled cRNA preparations, with a false 
discovery rate (FDR) set at 0.01.  A total of 1115 significant differences in gene expression were 
detected between the A2780CBNDXL and A2780CBN cell lines. Of these genes, 586 were up-
regulated in the A2780CBNDXL cell line compared to the A2780CBN cell line, while 547 were 
down-regulated (Table 3.9).  All differences in expression between the A2780CBNDXL and 
A2780CBN cell lines are described in Appendix I.    
 Comparison of Gene Expression between A2780CBNCC and A2780CBN Cells 3.2.2
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A2780CBNCC (P24) and A2780CC (P24) cells were cultured in drug-free medium for 48 hours, 
after which total RNA was extracted from both cell lines. All RNA preparations with RIN values 
between 9.0 and 10.0 were deemed suitable for microarray analysis. Using the same criteria as 
described for microarray-based comparisons between A2780CBNDXL and A2780CBN cells, a total 
of 3189 genes were identified whose expression was differentially expressed between 
A2780CBNCC and A2780 cells. Of these, 741 genes were up-regulated in the A2780CBNCC cell 
line compared to the A2780 cell line, while 2289 were down-regulated (Table 3.9).  All 
differences in gene expression between the A2780CBNCC and A2780 cell lines are described in 
Appendix II.    
 Comparison of Gene Expression between A2780CBNDXL and A2780DXL Cells 3.2.3
Gene expression differences between A2780CBNDXL and A2780DXL cells were identified using a 
“between array” comparison method (see section 2.4.6). Using the same criteria that were used 
in the above analyses, 3910 genes were up-regulated in the A2780CBNDXL cell line compared to 
the A2780DXL cell line, and 1805 were down-regulated, for a total of 5715 changes in gene 
expression (Table 3.9).  All differences in gene expression between the A2780CBNDXL and 
A2780DXL cell lines are described in Appendix III.   
 Comparison of Gene Expression between A2780CBNCC and A2780CC Cells 3.2.4
A similar “between array” comparison of gene expression was conducted using the microarray 
datasets comparing gene expression between the A2780CBNCC and A2780CC cell lines and 
between the A2780CBNDXL and A2780CBN cell lines.  This enabled us to identify 695 genes that 
were up-regulated in the A2780CBNCC cell line compared to the A2780CC cell line, and 490 that 
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were down-regulated, for a total of 1185 changes in gene expression (Table 3.9).  All changes in 
expression in the A2780CBNCC and A2780CC line are described in Appendix IV. 
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Table 3.9 Number of up-regulated, down-regulated and total gene expression changes in 
the four A2780CBN-variants comparison (FDR=0.01, p ≤ 0.05) 
Comparison Up-regulated  Down-regulated  Total  
A2780CBNDXL vs A2780CBN 586 547 1115 
A2780CBNCC vs A2780CBN 741 2448 3189 
A2780CBNDXL vs A2780DXL 3910 1805 5715 
A2780CBNCC vs A2780CC 695 490 1185 
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 Comparison of Gene Expression between A2780DXLCBN and A2780DXL Cells 3.2.5
Using RNA isolated from A2780DXLCBN and A2780DXL cells, identical microarray studies were 
conducted (using the same collection criteria) to identify 1418 genes  up-regulated in 
A2780DXLCBN cells compared to A2780DXL cells, and 1081 down-regulated genes (Table 3.10).  
All differences in gene expression between the A2780DXLCBN and A2780DXL cell lines are 
described in Appendix V.  
 Comparison of Gene Expression between A2780DXLCC and A2780DXL Cells 3.2.6
An identical approach also identified 5051 differences in gene expression between A2780DXLCC 
and A2780cc cells. Of these, 1420 genes were up-regulated and 3631 were down-regulated 
(Table 3.10).  All differences in gene expression between A2780DXLCC and A2780 cells are 
described in Appendix VI.   
 Comparison of Gene Expression between A2780DXLCBN and A2780CBN Cells 3.2.7
In yet another identical approach, 1503 genes were found to be up-regulated in A2780DXLCBN 
cells compared to A2780CBN cells, while 3268 were down-regulated, for a total of 4771 
changes in gene expression (Table 3.10).  All differences in gene expression between the 
A2780DXLCBN and A2780CBN cell lines are described in Appendix VII.  
 Comparison of Gene Expression between A2780DXLCC and A2780CC Cells 3.2.8
Finally, 783 genes were up-regulated (and 940 downregulated) in the A2780DXLCC cell line 
compared to the A2780CC cell line, for a total of 1723 differences in gene expression (Table 
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3.10). All differences in gene expression between the A2780DXLCC and A2780DXL cell lines are 
described in Appendix VIII. 
 
Table 3.10 Number of up-regulated, down-regulated and total gene expression changes in 
the four A2780DXL-variant comparison pairs (FDR=0.01, p ≤ 0.05) 
Comparison Up-regulated  Down-regulated  Total  
A2780DXLCBN vs A2780DXL 1418 1081 2499 
A2780DXLCC vs A2780DXL 1420 3631 5051 
A2780DXLCBN vs A2780CBN 1503 3268 4771 
A2780DXLCC vs A2780CC 783 940 1723 
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 Analyses of Gene Expression Profiles for Acquired and Previous Drug Resistance 3.3
 Gene Expression Changes Related to Acquisition of Docetaxel Resistance in 3.3.1
A2780CBNDXL Cells 
Our clonogenic studies of A2780CBNDXL cells suggested that docetaxel resistance is established 
when A2780CBN cells are selected for survival in increasing concentrations of docetaxel. The 
focus was then on how docetaxel resistance is established and whether previous carboplatin 
resistance is maintained and/or influenced by the new phenotype. In our microarray data 
analyses, the comparison between A2780CBNDXL vs. A2780CBN cells included gene expression 
changes that are likely associated with the acquisition of docetaxel resistance due to exposure to 
increasing concentrations of docetaxel in the absence of carboplatin. On the other hand, in the 
comparison between A2780CBNCC vs. A2780 cells, the gene expression changes would likely 
reflect the effects of long-term cell culture in the absence of carboplatin selective pressure. 
Therefore, by comparing the two sets of altered genes, we can likely differentiate genes key to 
the establishment of docetaxel resistance from genes associated with the loss of carboplatin 
selective pressure, which may reflect the effects of long-term cell culture in the absence of 
carboplatin selective pressure (Figure 3.8 C). The resulting list of 435 genes is featured in 
Appendix IX.  Of the genes associated with the acquisition of docetaxel resistance, we placed 
particular emphasis on those changing expression by 10-fold or greater (Table 3.11). ). 
Interestingly, 8 of the 14 genes listed in Table 3.11 also differentially expressed  in the original 
A2780DXL line, when  compared to the parental A2780 line, indicating an association with 
docetaxel resistance. Some of the genes, for example CFH, RND3, PRR7, PRL showed changes 
in opposite direction from the original A2780DXL line while BEX1, HAPLN1, SULF2, and 
ATP6V0D2 changed in the same direction (upregulation) although usually to a greater extent in 
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the reverse selected A2780CBNDXL cell line.(unpublished data provided by Dr. Carita Lannér. 




Figure 3.8 Gene Expression differences between the A2780CBN cell line and the 
A2780CBNDXL,  A2780CBN, and A2780CBNCC cell lines 
(A) Gene expression changes in A2780CBNDXL vs. A2780CBN; (B) Gene expression changes in 
A2780CBNCC vs. A2780CBN. (C) After merging two sets of comparisons, 435 unique gene 
changes appear to be associated with the establishment of docetaxel resistance in the 
A2780CBNDXL cell line. 
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Table.3.11 Gene expression changes (>10-fold) upon establishment of docetaxel resistance 
in the A2780CBNDXL cell line.   
These genes are unrelated to those changing expression upon loss of carboplatin selective 
pressure. 
Gene name Protein name Fold change A2780CBNDXL 
vs A2780CBN 
p for fold 
change 
fold change A2780DXL 
vs. A2780 (1) 
CFH Complement Factor H -13.99 10.9 x 10-4 2.19 
AKR1C1 aldo-keto reductase family 1, member C1 -11.76 1.54 x 10-4 -6.35 
CFHR3  complement factor H-related  -11.61 2.76 x 10-4 6.48 
A2M Alpha-2-Macroglobulin -10.39 8.22 x 10-4  
RND3 Rho family GTPase 3 15.31 4.22 x10-4 -2.00 
BEX1 brain-expressed X-linked protein 1 15.50 4.10 x 10-4 -10.00 
PRR16 proline rich 16 15.99 7.22 x 10-4 6.23 
PRL Prolactin 16.63 6.89 x 10-4  
HAPLN1 hyaluronan and proteoglycan link protein 1 17.13 1.04 x 10-4 2.66 
SULF1 Sulfatase 1 18.36 2.84 x 10-4 2.29 
MECOM MDS1 and EVI1 complex locus 20.32 5.00 x 10-4  
SLITRK6 SLIT and NTRK-like family, member 6 21.75 5.40 x 10-4  
ATP6V0D2 ATPase, H+ transporting, lysosomal 
38kDa, V0 subunit d2 
35.69 6.93 x 10-4  
(1) Unpublished data provided by Dr. Carita Lannér.  
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 Microarray Analyses Support No Significant Expression Changes for Genes Associated 3.3.2
with Carboplatin Sensitivity in the A2780CBNDXL and A2780CBNCC Cells 
The previous clonogenic assay results showed that carboplatin sensitivity (the IC50) for 
A2780CBNDXL cells was similar to that of A2780CBNCC cells, when each cell type was compared 
to A2780CBN cells (i.e. not significantly different from a statistical point of view). These two cell 
lines were not compared directly to one another. This suggests that the carboplatin resistance 
phenotype in A2780CBN cells was not lost upon withdrawal of carboplatin selective pressure, 
even if this involved exposure to a new chemotherapy agent (docetaxel). Previous microarray 
studies published by Armstrong et al. 150suggested that down-regulation of ANXA1 and up-
regulation of CDH7, GLCL, GSTO1 and PARP9 were related to acquired carboplatin resistance 
by comparing gene expression between A2780CBN and A2780 cells (Table 3.12).  To know if the 
expression of these 5 genes was altered by carboplatin withdrawal in the current study, I 
searched the gene names in the microarray data files comparing gene expression between 
A2780CBNDXL and A2780CBN cells and between A2780CBN-CC and A2780CBN cells.  This analysis 
showed that the expression of the above 5 genes was not significantly changed upon withdrawal 
from carboplatin selective pressure, except for GCLC (which encodes the glutamate-cysteine 
ligase catalytic subunit). The expression of this gene was down-regulated approximately 2-fold 
upon withdrawal of carboplatin selective pressure.  In contrast, GCLC was up-regulated 8.5 
times in Armstrong et al.’s comparison of gene expression between A2780CBN and A2780 cells. 
Therefore, expression of these genes were not altered upon selection of A2780CBN cells for 
resistance to docetaxel (A2780CBNDXL cells) or upon withdrawal of carboplatin selective 
pressure in A2780CBN cells (A2780CBNCC cells).  
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Table 3.12 The comparison of gene expression related to carboplatin resistance in 





General function Fold change 
A2780CBN vs 
A2780(1) 
P(1) Fold change 
A2780CBNDXL 
vs A2780CBN 









-104.15 1.38x10-4 N/A (2) N/A N/A N/A 
CDH7 Cadherin 7 
 
Cell to cell adhesion 
glycoprotein 






Rate limiting enzyme 
of glutathione 
synthesis 
8.50 5.85x10-5 -2.18 8.65x10-5 -2.44 1.62 x 10-5 







glutathione to toxic 
substrates 






Catalyzes addition of 
ADP-ribose moieties 
to substrate proteins 
9.40 1.95x10-3 N/A N/A N/A N/A 
(1) Data retrieved from previous work: S. Armstrong, R. Narendrula, Baoqing Guo, A. Parissenti, K. McCallum, S. 
Cull, C. Lannér. Distinct genetic alterations occur in ovarian tumour cells selected for combined resistance to 
carboplatin and docetaxel. Journal of Ovarian Research. 2012, 5:4  
(2) No fold changes were identified in the paired cell lines. 
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 Gene Expression Changes Related to Acquisition of Carboplatin Resistance in 3.3.3
A2780DXLCBN Cells  
According to clonogenic assay data, carboplatin resistance was achieved in the established 
A2780DXL→CBN cell line by exposing A2780DXL cells to carboplatin in the absence of docetaxel. 
On the other hand, the gene expression changes identified from microarray experiments 
involving A2780DXLCBN and A2780DXL cells would be expected to include genes involved in 
both the establishment of carboplatin resistance (Armstrong et al.) and the loss of docetaxel 
resistance after long term culture.  Meanwhile, since docetaxel resistance was also lost upon 
removal of docetaxel selective pressure in A2780DXLCC cells (confirmed by clonogenic assays), 
the gene expression changes identified in microarray experiments comparing A2780DXLCC cells 
with A2780DXL cells would be expected to be associated with the loss of docetaxel resistance. 
Therefore, we merged the data from two comparison pairs, (A2780DXLCBN cells vs. A2780DXL 
cells and A2780DXLCC cells vs. A2780DXL cells), to exclude genes associated with docetaxel 
resistance loss (Figure 3.9 D) in order to reveal the genes specifically associated with acquisition 
of carboplatin resistance (Figure 3.9 C). Through this approach, 1319 unique changes in gene 
expression were identified to be associated with the acquisition of carboplatin resistance 
[A2780DXLCBN cells vs. A2780DXL cells (Figure 3.9 C)]. These genes are listed in Appendix X.  
Among these genes, we noted those changing expression by 10-fold or greater (Table 3.14).  
Several of these genes are involved in apoptotic pathways (BEX1 161, Brain-expressed X-linked 
protein 1; BCL6 162–164, B-cell CLL/lymphoma 6; CYB5A 165,166, cytochrome b5 type A; CYB5R2, 
cytochrome b5 reductase 2; SLC25A24 167–169, solute carrier family 25 member 24; and FAS 
170,171, cell surface death receptor).   
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Figure 3.9 Gene expression differences between A2780DXLCBN and A2780DXL cells and 
between A2780DXLCC and A2780DXL cells 
(A) Gene expression differences between A2780DXLCBN and A2780DXL cells; (B) gene 
expression differences between A2780DXLCC and A2780DXL cells; (C) common gene expression 
differences between (A) and (B) that may be associated with the loss of docetaxel resistance; (D) 
unique gene expression changes that may be associated with carboplatin resistance establishment 
in the A2780DXLCBN cell line. 
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Table 3.13 Gene expression differences that may be related to the establishment of 
carboplatin resistance in the A2780DXLCBN cell line 
Gene name Protein name General function 
Fold change      
A2780DXLCBN vs. 
A2780DXL 
p for fold change 
BEX1 Brain-expressed X-
linked protein 1 
Inhibition of 
apoptosis by down-
regulation of hBEX1 
-137.99 3.92 x 10-5 
BCL6 B-cell CLL/lymphoma 6 Apoptosis inhibitor 15.52 3.82 x 10
-4 
CYB5A cytochrome b5 type A Autophagy induction -25.48 1.23 x 10
-4 
CYB5R2 cytochrome b5 
reductase 2 
drug metabolism -10.15 1.09 x 10
-5 





793.5 7.6 x 10-5 
FAS 
Fas cell surface death 
receptor 
 
death receptor on the 
surface of cells 
leading apoptosis 




transcription factor 2 
ABCB1 binding 
factor 
220.32 1.31 x 10-4 




506.23 7.01 x 10-5 
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 Possible Gene Expression Changes Associated with Diminished Docetaxel Resistance in 3.3.4
A2780DXLCBN and A2780DXLCC Cells 
According to clonogenic assay results involving the A2780DXLCBN and A2780DXLCC cell lines, 
docetaxel resistance was still observed (but at a substantially lower level) after removal of 
docetaxel selective pressure. The focus then became on how docetaxel resistance became 
reduced in those cells.  Previous microarray data 150 (Armstrong et al.) suggested that up-
regulation of ABCB1 (33.6-fold) and ABCB4 (141-fold) expression, and down-regulation of 
CYP1B1 expression (-38 fold) were associated with acquisition of docetaxel resistance 
[comparison of A2780DXL and A2780 cells (table 3.14)].  To determine whether these genes were 
also altered by docetaxel withdrawal, we examined the expression data for the above genes in the 
microarray comparisons between A2780DXLCBN cells and A2780DXL cells and between 
A2780DXLCC cells and A2780DXL cells. This analysis showed that the above three genes did, 
again, exhibit changes in gene expression, but in the opposite direction. ABCB1 expression was 
down-regulated 15-28 times, while ABCB4 was downregulated 9-131 times. CYP1B1 expression 
was upregulated 6-68 times (Table 3.14).  This comparison suggests that these genes are truly 
associated with docetaxel resistance, as they changed in the positive direction upon acquisition 
of docetaxel resistance and, in tandem, in the negative direction when docetaxel selective 
pressure was removed and docetaxel resistance was lost.   
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Table 3.14 Genes related to reduced docetaxel resistance in microarray studies 
Gene    


























−37.77 2.0x 10-8 67.54 7.2 x 10-5 5.96 4.34 x 10-6 
ABCB1 
ATP-binding 








33.62 8.2 x 10-11 -27.8 1.6 x 10-6 -14.73 6.59 x 10-8 
ABCB4 
ATP-binding 








141.27 5.8 x 10-10 -130.99 1.2 x 10-4 -9.25 2.7 x 10-7 
(2) Data retrieved from previous work (S. Armstrong, R. Narendrula, Baoqing Guo, A. Parissenti, K. 
McCallum, S. Cull, C. Lannér. Distinct genetic alterations occur in ovarian tumour cells selected for 
combined resistance to carboplatin and docetaxel. Journal of Ovarian Research. 2012, 5:4
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Chapter 4  
4. Discussion 
Ovarian cancer remains the leading cause of death for gynecologic malignancies in North 
America 1,2. Chemotherapy still plays a major role in treatment and is employed after surgery 
(adjuvant chemotherapy), although neoadjuvant chemotherapy has been used to treat some 
ovarian cancer patients with reasonable efficacy 3,4.  Since the 1990s, the combination of taxane 
and platinating agents became the preferred (standard) regimen for chemotherapy treatment of 
ovarian cancer patients 2,18–20,172.  The initial response rate for this regimen can be as high as 
70%, but eventually these patients will relapse and possess chemo-resistant tumours 18.  Thus, 
the 5-year survival rate post-treatment remains low statistically. Innate or acquired drug 
resistance in tumours is one of the major obstacles to the effective treatment of advanced ovarian 
cancer.  To understand the mechanisms contributing to drug resistance in ovarian tumour cells, 
our lab has focused its efforts on characterizing newly established ovarian tumour cell lines that 
have been selected for resistance to a platinating agent (after resistance to a taxane has been 
achieved) and  selected for resistance to a taxane (after resistance to a platinating agent has been 
achieved).  We hypothesized that exposure to platinating agents may rapidly re-establish tumour 
cell sensitivity to taxanes and vice versa, possibly at a faster rate than by simple drug 
withdrawal. 
In the end of the experiments, each cell line underwent microarray analysis to identify changes in 
gene expression that accompany loss of selection pressure and/or acquisition of resistance to a 
new chemotherapy agent.  
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The drugs used in our study included both carboplatin and docetaxel, since the original resistant 
A2780 cell lines had been derived using these agents and because there was no cross resistance 
between these drugs 150. Carboplatin was chosen as the platinating agent because it is clinically 
preferred, with less toxicity and longer lasting effects when compared to cisplatin 56.  Docetaxel 
was chosen for the study because docetaxel also has a more favorable toxicity profile, since its 
major toxic side effect (neutropenia) can be managed with other agents such as pegfilgrastim 
173,174, and since docetaxel does not induce the same degree of neuropathy as paclitaxel 82,175. 
During the selection process for carboplatin or docetaxel resistance, the drug concentration was 
gradually elevated from the first selection dose (S1) to the maximally tolerated dose. Dead cells 
were observed in the culture flask during selection, suggesting that some of the cells were unable 
to survive while other cells possessed or developed resistance to the drugs at the specific 
selection doses. It is notable that at the end of the selection for the A2780DXL→CBN subline, these 
cells exhibited a clear morphology change compared to the  A2780DXL cell line from which it 
was derived (Fig 3.1). A2780DXL→CBN cells were more spindle-shaped compared to the oval-
shaped A2780DXL cells. Meanwhile, a morphology change was not observed when A2780CBN 
cells were selected for resistance to docetaxel (A2780CBN→DXL cells).  This suggests that the 
morphology change is associated with acquisition of carboplatin resistance after prior selection 
for docetaxel resistance (and not vice versa). In many studies, this kind of morphology change of 
A2780DXL→CBN cells takes place during the epithelial mesenchymal transition (EMT) 176,177. Cells 
undergoing EMT usually exhibit loss of epithelial polarity, increased motility and migration 
characteristics 178,179, suggesting that they have progressed to a more invasive state. Therefore, 
the changes in morphology (round to spindle for the transition from A2780DXL cells to 
A2780DXLCBN cells) are considered to be associated with increased tumour aggressiveness. 
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Moreover, studies also have shown that EMT can be related to drug resistance in different 
cancers. According to Sayan et al., the expression of EMT-associated genes ZED2 and SIP1 in 
muscle-invasive urothelial cancer cells protects the cells from DNA damage-induced apoptosis 
180.  
In our microarray studies, when comparing gene expression changes between A2780DXLCBN and 
A2780DXL cells (see Appendix V), several genes related to EMT are identified through cross-
referencing with Qiagen’s list of genes associated with the EMT in their EMT PCR array 
(http://www.sabiosciences.com/rt_pcr_product/HTML/PAHS-090Z.html) 181-182.  
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Table 4.1 EMT related genes that exhibit expression change as A2780DXLcells are selected 
for resistance to carboplatin (A2780DXL→CBN cells) 
Gene name Protein name General function 
Fold change      
A2780DXLCBN vs. 
A2780DXL 
p for fold change 
ITGAV Integrin subunit alpha V vitronectin receptor 4.65 1.29x10-5 
MMP3 Matrix metallopeptidease 3 
Degrade fibronectin, 
laminin, collagens,  
73.47 4.75x10-4 
S100A4 
S100 calcium binding 
protein A4 
motility, invasion, and 
tubulin polymerization 
2.22 1.19x10-3 
SDC2 syndecan 2 




SPARCL1 SPARC like 1 Cell migration 8.46 5.27x10-4 





vacuolar protein sorting 13 
homolog A 
cycling of proteins 
through the trans-Golgi 
network  
2.15 1.05x10-3 
COL2A1 collagen type II alpha 1 fibrillar collagen -5.66 2.81x10-4 
SPP1 secreted phosphoprotein 1 bone mineralization -69.08 7.11x10-6 
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Clonogenic assays were performed for quantification of cellularity sensitivity to the above 
chemotherapy drugs. This assay is considered to be more sensitive and more accurate than high 
throughput colorimetric , such as the 3-(4, 5-dimethylthiazol-2-yl) 2, 5-diphenyl-tetrazolium 
bromide (MTT) assay. The MTT assay indirectly measures cell viability by quantifying the 
ability of a mitochondrial dehydrogenase enzyme in cells  to convert the tetrazolium salt into 
formazan 183.  However, the enzyme exists not only in metabolically active cells but also in dead 
cells 184,185. This results in the MTT assay overestimating cell viability.  It is therefore not as 
accurate as the clonogenic assay (despite its ease of use).  
In previous studies, resistance to docetaxel (A2780DXL cells) and carboplatin (A2780CBN cells) 
were established by treating A2780 cells with increasing doses of docetaxel or carboplatin, with 
retention of surviving cells 186. The resistant cell lines were very stable in liquid nitrogen storage.  
The clonogenic assay results (Fig 3.2) indicated that the A2780CBN→DXL cell line exhibits 
considerably greater resistance to docetaxel than parental A2780CBN cells. The IC50 for docetaxel 
of A2780CBN→DXL cells was 76 times higher than that of A2780CBN cells and 4 times lower than 
that of A2780DXL cells. However, there was no statistically significant difference in docetaxel 
sensitivity (IC50) between A2780CBN→DXL and A2780DXL cells (p=0.05, table 3.3), indicating that 
the degree of docetaxel resistance in the A2780CBN→DXL cell line is comparable to the A2780DXL 
line. On the other hand, resistance to carboplatin was not significantly reduced in A2780CBN cells 
after 25 passages (88 days) in the absence of carboplatin (A2780CBN→CC cells; p=0.18, Figure 
3.6). The results also showed that the IC50 for carboplatin of both A2780CBN and A2780CBN→DXL 
cells were significantly higher than that of A2780 parental cells (p=0.03, p=0.03 table 3.4). 
Therefore, while the A2780CBN→DXL cell line acquired docetaxel resistance upon docetaxel 
exposure and withdrawal from carboplatin (Table 3.3: A2780 CBN→DXL compared to A2780CBN, 
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p=0.008), the original resistance to carboplatin was not significantly altered (Table 3.4: 
A2780CBNDXL compared to A2780DXL, p=0.19). This suggested that the previous mechanism(s) 
for carboplatin resistance was retained, even upon acquisition of docetaxel resistance.  
Alternatively, the newly acquired docetaxel resistance mechanisms also facilitate resistance to 
carboplatin.  To address this issue, the original resistant cell line A2780CBN was continually sub-
cultured without any drug to the same passage number of A2780CBN→DXL cells. The results 
(Figure 3.6) showed that the IC50 for carboplatin was reduced about 3.6 times in A2780CBN→CC 
cells compared to A2780CBN cells, but the IC50 for A2780CBN→CC cells was still significantly 
higher than A2780 parental cells (table 3.7: p=0.013). Taken together, the results suggest that 
once carboplatin resistance is established in A2780 cells, the resistance phenotype is very stable. 
Thus, removal of carboplatin from the cells for 88 days, the so called “drug free interval”, did 
not restore their sensitivity. This then suggested that the persistence of carboplatin resistance in 
A2780CBN→DXL cells was independent of the acquisition of docetaxel resistance. 
While the A2780CBN→DXL and A2780DXL cells share a somewhat similar degree of resistance to 
docetaxel, the microarray comparison did not identify a common gene profile typical of taxane 
resistance, for example, changes in drug transporters. However, it is interesting that of the 14 
changes in gene expression of 10-fold or more, possibly associated with acquisition of docetaxel 
resistance in the A2780CBN→DXL cell line (Table 3.11), 8 were found in the A2780DXL microarray 
data. Four of the changes were in the opposite direction in the cell lines, but the other four 
changes were in the same direction, namely upregulation of expression of the BEX1, HAPLN1, 
SULF1/SULF2, and the ATP6V0D2 genes (Table 3.11a). The BEX1 gene is known to play a role 
in neuronal development, but is widely expressed in other tissues, including in breast cancer. 
BEX1 is considered to be a tumour suppressor and has been shown to overcome imatinib 
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resistance 161. The HAPLN1 gene encodes the Hyaluronan and proteoglycan link protein 1, which 
is expressed in ovarian granulosa cells and facilitates cell survival 187. HAPLN1 is also 
upregulated in metastatic cancer cell lines and tumours, where it promotes Extracellular Matrix 
(ECM) development, which can contribute to drug resistance. SULF1 expression was found 
upregulated in the A2780CBN→DXL cell line (18.36 fold) and SULF2 in the A2780DXL line (2.66) 
188,189. Both SULF1 and SULF2 are arylsulfatases which can desulfate heparin sulfate 
proteoglycans in the ECM 190. While SULF1 and SULF2 appear to have similar enzymatic 
properties the biological outcomes of their signaling are opposite. SULF 1 has anti-tumourigenic 
properties but has been shown to affect cisplatin resistance in ovarian cancer, while SULF2 
appears to play a tumourigenic role, promoting tumour growth in several cancer types 191. 
Finally, the ATP6V0D2 gene codes for a proton pump that protects cells against external 
acidosis, a common feature of solid tumours, which can stimulate cellular adaptations to promote 
survival 192,193. While all these genes do not immediately appear to have a direct link to taxane 
resistance, they all affect cell growth and survival which may ultimately contribute to the 
survival of A2780CBN→DXL cells during exposure to docetaxel (in addition to drug transporters 
and other genes that already have altered expression in A2780DXL cells). 
Previous microarray data (Table 3.13) suggested that down-regulation of ANXA1 gene 
expression (104-fold) and up-regulation of CDH7 (2.8-fold), GCLC (8.5-fold), GSTO1 (2.4- 
fold) and PARP9 (9.4-fold) expression were associated with the acquisition of carboplatin 
resistance in A2780 cells 150. Interestingly, there was no difference in the expression of these 
genes between A2780CBN cells and either A2780CBN→DXL cells or A2780CBN→CC cells (p< 0.001), 
except for GCLC, whose expression in A2780CBN→DXL cells was 2-fold lower compared to 
A2780CBN cells (p=8.65 x 10-5). This may indicate that down regulation of ANXA1 and 
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upregulation of CDH7, GSTO1 and PARP9 are important for retention of carboplatin resistance, 
while GCLC may not be. 
The CDH7 gene encodes for Cadherin 7, a calcium-dependent phospholipid-binding protein 194. 
CDH7 plays a role in cell adhesion. Its relevance to cancer resistance is not well known. PARP9 
gene encodes for Poly-ADP-ribose polymerase family member 9 and it functions to catalyze 
addition of ADP-ribose moieties to substrate protein 195. PARP9, a.k.a BAL1, has been shown to 
participate in the DNA repair pathway initiated by PARP1, which suggests that upregulated 
PARP9 in the A2780CBN and A2780CBN→DXL cell lines could contribute to DNA repair, a known 
mechanism of resistance to carboplatin 196. The ANXA1 gene product Annexin I belongs to the 
annexin family of Ca2+-dependent phospholipid-binding proteins 197. It is preferentially located 
on the cytosolic face of the plasma membrane and has phospholipase A2 inhibitory activity. It 
has been reported that down-regulated ANXA1 expression contributes considerably to drug 
resistance in erythroleukemia K562 cells line 198. When ANXA1 is silenced or lost in cancer, cells 
are more prone to DNA damage, suggesting an unidentified diverse role in genome maintenance 
or integrity 199.   
The GCLC gene product (Gamma-glutamylcysteine synthetase) functions as rate-limiting 
enzyme involved in glutathione synthesis 200, while the GSTO1 gene product is a specific 
isoform (omega 1) of Glutathione S-transferase (GST). Glutathione is an important antioxidant 
in plants, animals, fungi and some bacteria and archaea, preventing damage to important cellular 
components caused by reactive oxygen species (ROS) such as free radicals and peroxides 122–
124,126. The GSTs are a family of isoenzymes. Their best known function is to catalyze the 
conjugation of the reduced form of glutathione (GSH) to xenobiotic substrates for the purpose of 
drug detoxification 127. There is a growing body of evidence supporting the role of GST, 
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particularly GST-P, in cancer development and chemotherapeutic resistance and GSTO1 likely 
plays a similar role 201. 
Using the same approach as described above (Chapter 2 Materials and Methods 2.2), we were 
able to select A2780DXL cells for resistance to carboplatin (Fig 3.4): the A2780DXL→CBN cell line.  
The IC50 of A2780DXL→CBN cells for carboplatin was 24 times higher than that of A2780DXL cells 
(Figure 3.4, t-test, p=0.0002). In contrast, there was no significant difference between the 
A2780DXL→CBN and A2780CBN cell lines in terms of their IC50s for carboplatin. Resistance to 
docetaxel, however, was reduced 135 times after long term incubation in the absence of 
docetaxel (29 passages, 102 days), i.e. upon comparison of the docetaxel sensitivity of 
A2780DXL→CC cells and A2780DXL cells (t-test, p=0.03). Interestingly, the IC50 for docetaxel in 
A2780DXL→CBN cells was 3.6 times higher than that of A2780 parental cells but there was no 
significant difference in docetaxel sensitivity between the two cell lines (t-test, p=0.2). 
Therefore, the above results indicated that resistance to carboplatin was achieved in the 
A2780DXL→CBN, with a concomitant restoration of docetaxel sensitivity.   
It should also be noted that docetaxel resistance was also significantly decreased in 
A2780DXL→CC cells when compared to A2780DXL cells (p=0.03), but the IC50 for docetaxel in 
A2780DXL→CC  cells (550.2 ± 0.29 nM) cells was higher than that of A2780DXL→CBN cells (1.76 ± 
0.81 nM). Our results thus suggest that the degree of restoration in docetaxel sensitivity was 
greater upon selection for carboplatin resistance than by simply removing docetaxel selective 
pressure.  Previous microarray data (Table 3.15 A2780DXL vs. A2780) suggested that docetaxel 
resistance in A2780DXL cells was highly related to down-regulated expression of CYP1B1 (38-
fold) and up-regulated ABCB1 (34-fold) and ABCB4 (141-fold) expression. Consistent with their 
roles in docetaxel resistance, we observed that the expression of these genes changed in the 
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opposite direction upon selection for carboplatin resistance (A2780DXLCBN vs. A2780DXL cells) 
or upon elimination of docetaxel selective pressure (A2780DXLCC vs. A2780DXL).  CYP1B1 is a 
member of the cytochrome P450 family (isoform 1B1) 202.  It is a phase 1 drug metabolizing 
enzyme,  which was found to be heavily over-expressed in ovarian cancer cells compared to 
normal ovary tissue 203.  It has been proposed to be a leading cause of resistance of cancer cells 
to cytotoxic drugs, including both platinating agents and taxanes 204.  Interestingly, it is thought 
that resistance to docetaxel associated with CYP1B1 over-expression may be due to Cyp1b1’s 
ability to bind docetaxel (not to break it down), thereby reducing the amount of active drug in 
tumour cells 205. However, since the expression of CYP1B1 was found to be down-regulated in 
the A2780DXL cell line in a previous study 186, it is possible that inhibiting taxane detoxification 
by Cyp1b-mediated metabolism also played a role in docetaxel resistance in A2780 ovarian 
tumour cells. In Sissung et al. 204, a different role for Cyp1b1 in resistance to taxanes was 
suggested. Cyp1b can oxidize estrogen and the oxidized estrogen metabolite inhibits tubulin 
polymerization. In this scenario, low levels of Cyp1b would restore tubulin polymerization and 
allow cells to proliferate. This may explain how reduced expression of CYP1B1 can contribute 
to resistance to taxanes. CYP1B1 expression is significantly down regulated in the A2780DXL 
line according to S. Armstrong et al. 150. Further experiments augmenting or reducing Cyp1b1 
protein expression in wildtype and docetaxel-resistant A2780 cells, respectively, should be 
conducted to test the relationship between Cyp1b1 expression and docetaxel sensitivity. 
Immunoblotting procedures or CYP1B1 transcript quantitation by qPCR could then be used to 
determine whether Cyp1b1 expression truly affects docetaxel sensitivity in ovarian tumour cells. 
Data presented in this thesis indicated that the fold difference in CYP1B1 expression between 
A2780DXLCBN and A2780DXL is 67 (p=7.2 x 10
-5), which is greater than the 6.0-fold elevation in 
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CYP1B1 expression found in A2780DXLcc cells compared to A2780DXL cells (p=4.34 x 10
-6). 
This suggests that the greater restoration of docetaxel sensitivity may be related to a greater 
elevation in CYP1B1 expression.  
The ABCB1 and ABCB4 genes code for ATP-binding cassette (ABC) transporter subfamily 
members B1 and B4, which are multidrug transporters that mediate the ATP-dependent efflux of 
a variety of chemotherapy drugs from tumour cells 137,206. Several ABC transporters (such as 
Abcb2, Abcb1, Abcc1, Abcc2, Abcc4, and Abcg2) have been found to be overexpressed in cell 
lines selected for resistance to chemotherapy drugs 207–210. Human Abcb1 (MDR1/P-gp) is one of 
the most widely studied transporters in drug resistance, and has been implicated not just in 
resistance to anti-cancer drugs but numerous other drugs as well 211. Therefore, ABCB1 and 
ABCB4 up-regulation likely played a role in the observed docetaxel resistance found in 
A2780DXL cells by Armstrong et al. 150.  Consistent with this view, we observed that ABCB1 and 
ABCB4 expression were down-regulated 28- and 131-times, respectively, in A2780DXL→CBN 
cells, which could account for the restoration in docetaxel sensitivity.  A previous study showed 
that in vitro selection of cells resembles the in vivo acquisition of the MDR phenotype, but 
resistant cells have to be cultured under constant selective pressure to ensure a stable phenotype 
212.  The downregulation of ABCB1 expression seen in our microarray data would help explain 
the loss of docetaxel resistance in A2780DXLCBN cells, as seen in our clonogenic studies. 
According to microarray data (Table 3.15), ABCB1 and ABCB4 are both downregulated upon 
selection of A2780DXL cells for carboplatin resistance (27.8 fold and 130 fold, respectively) or 
upon removal of docetaxel selective pressure (A2780DXLCC cells; 14.73 fold and 9.25 fold, 
respectively). This suggests that greater suppression of Abcb1 and Abcb4 expression is 
associated with greater loss of docetaxel resistance loss. Moreover, selection for carboplatin 
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resistance induces a greater downregulation in the expression of these drug transporters than 
simply eliminating docetaxel selective pressure. 
While our clonogenic assays confirmed the establishment of docetaxel resistance in the 
A2780CBN→DXL cells, no change in the expression of CYP1B1, ABCB1 and ABCB4 was observed 
upon acquisition of docetaxel resistance to create the A2780CBN→DXL cell line (Table 3.11).  As 
the original carboplatin resistance persists in the A2780CBN→DXL cells, it appears to be a dual 
drug resistant cell line (resistant to both carboplatin and docetaxel). This may account for the 
gene expression differences between the original A2780DXL cell line and A2780CBN→DXL cells, 
both of which exhibit docetaxel resistance. Since the dual drug resistant cell line A2780CBNDXL 
has been established previously, it might be valuable to compare differences in gene expression 
between A2780CBN→DXL and A2780CBNDXL cells in microarray studies.  To investigate the 
mechanisms behind drug resistance, microarray analysis was performed, comparing gene 
expression between A2780CBN-variants (Table3.3) and A2780DXL-variants (Table 3.4). Based on 
clonogenic assay data, carboplatin resistance was established and original docetaxel resistance 
was lost in A2780DXLCBN cells; docetaxel resistance was also lost in A2780DXLCC cells.  Thus, 
differences in gene expression between A2780DXL→CBN cells and A2780DXL cells would be 
expected to be associated with the acquisition of carboplatin resistance and/or the loss of 
docetaxel resistance.  In contrast, differences in gene expression between A2780DXLCC vs 
A2780DXL would likely be related to loss of docetaxel resistance only. We thus hypothesized that 
genes in common between the two groups would represent genes associated with loss of 
docetaxel resistance, while the unique genes within the two sets would more likely to be related 
to carboplatin resistance establishment (Table 3.5) 
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Among 8 notable gene expression changes associated with selection of A2780DXL cells for 
resistance to carboplatin, BEX1, CYB5A, CYB5R2, and FAS were down-regulated, while BCL6, 
SLC25A24, PIX2 and EMP1 were up-regulated.  BEX1 was down-regulated 138 times when the 
A2780DXLCBN cell line was established.  A study in 2009 demonstrated that the gene for brain 
expressed X-linked 1 protein (BEX1) was silenced in secondary imatinib-resistant human 
erythroleukemia K562 cell line 213 . Re-expression of BEX1 in this cell line restored imatinib 
sensitivity, resulting in the induction of apoptosis 213.  
The BCL6 gene was up-regulated 15.5 times in A2780DXLCBN cells (table 3.14: p=3.82x10
-4). 
The protein encoded by BCL6 gene is an evolutionarily conserved zinc finger transcription 
factor. It acts as a sequence-specific repressor of transcription 163. Overexpression of BCL6 in 
mouse C2C12 myocytes enhanced cell viability by preventing apoptosis.  High levels of Bcl6 
antisense mRNA expression induced apoptosis during the differentiation of C2C12 cells, but this 
was effectively prevented by infection with an adenovirus that expressed a Bcl6 sense mRNA 
164. Another study by the same research group also reported that BCL6 overexpression 
significantly inhibited apoptosis caused by etoposide.  BCL6 overexpression was found to inhibit 
the increase in ROS levels and apoptosis in response to etoposide and other chemotherapeutic 
reagents 162.   
CYB5A and CYB5R2 code for cytochrome b5 type A and cytochrome b5 reductase 2 
respectively. Both of the two genes were down-regulated 25.5 (Table 3.14 p=1.23x10-4) and 10 
times (Table 3.14  p=1.09x10-5), respectively, after carboplatin resistance establishment in 
A2780DXLCBN cells.  Cytochrome b5 is a membrane bound hemoprotein which functions as an 
electron carrier for several membrane bound oxygenases 214.  A significant correlation was seen 
between shorter survival and loss of the 18q22.3 in the highly invasive and resistant cells of 
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pancreatic cancer. Further investigation revealed that CYB5A had a prognostic value in 
metastatic patients 215.  Moreover, both in vitro and in vivo studies clarified a role for CYB5A in 
inhibiting the activity of oncogenic phenotypes through induction of a well-known survival 
pathway in tumor cells (autophagy) 165,166. 
SLC25A24 was found to be up-regulated 794-fold in A2780DXLCBN cells compared to A2780DXL 
cells (table 3.14 p=7.6x10-5). The gene is a member of the mitochondrial carrier subfamily of 
solute carrier protein genes. The product of this gene, solute carrier family 25 member 24, 
functions as a gated pore that translocates ADP from the cytoplasm into the mitochondrial matrix 
and ATP from the mitochondrial matrix into the cytoplasm 167. The protein forms a homodimer 
embedded in the inner mitochondria membrane 168,169. It has been shown that suppressing the 
expression of this gene induces apoptosis and inhibits tumour growth. SLC25A24 has been listed 
as one of several chemo-resistance genes in a previously published microarray study 186. 10 
human tumour cell lines, including parental cells and resistant sub cell lines selected for 
resistance against doxorubicin, melphalan, teniposide and vincristine were studied 216–218.  
The FAS gene encoding the Fas receptor (FasR) was down-regulated 11-fold as carboplatin 
resistance was established in the docetaxel resistant cell line (t-test, p=1.23 x 10-5).  The Fas 
receptor is a death receptor on the surface of cells that leads to programmed cell death, which is 
one of two regulated apoptotic pathways 170,219.  Binding of Fas ligand (FasL) to Fas receptor 
(FasR) induces trimerization of FasR, which recruits caspase-8. The oligomerization of caspase-
8 may result in self-activation of proteolytic activity and trigger protease cascade (caspases) 220. 
The activated caspases can induce apoptosis, resulting in the cleavage of various substrates, such 
as poly-ADP-ribose polymerase (PARP), lamin, rho-GDI, and actin, and the induction 
morphological changes to the cells and nuclei 221,222.  
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PITX2 was up-regulated 220-fold when carboplatin resistance was established in the A2780DXL 
cell line. The protein encoded by the PITX2 gene, Pitx2, acts as a transcription factor. It is 
responsible for the asymmetrical development of the heart, lungs, spleen, and the eyes 223. Pitx2 
is over-expressed in many cancers 224–227. Increased expression of the Pitx2 transcription factor 
has been found in ovarian cancer cells when compared to noncancerous cell lines 224. In renal 
cancer, Pitx2 regulates expression of ABCB1 by binding to the promoter region of ABCB1. 
Therefore, increased expression of PITX2 in renal cancer cells is associated with increased 
expression of Abcb1 and so have a greater resistance to chemotherapeutic agents 225. Other 
studies have shown that PITX2 is also overexpressed in human esophageal squamous cell 
carcinoma (ESCC) compared to normal esophageal squamous cells and greater expression of 
Pitx2 is positively correlated with clinical aggressiveness of ESCC 226. However, in the 
A2780DXLCBN cell lines, docetaxel resistance is not elevated. This is further confirmed by the 
downregulation of ABCB1 (Appendix V). This might mean the protein level of Pitx2 is not 
correlated with gene PITX2, which need to be confirmed by western blot. On the other hand, the 
correlation between carboplatin resistance and PITX2 remains to be studied. 
The EMP-1 gene was up-regulated 506 times in A2780DXLCBN cells compared to A2780DXL 
cells. Interestingly, the expression of its gene product (a surface biomarker) was found to be 
correlated with gefitinib resistance 228. EMP-1 expression was further correlated with the 
complete lack of response or partial response to gefitinib in lung cancer patient samples, as well 
as clinical progression to secondary gefitinib resistance 229. This report thus suggests a role of the 
adhesion molecule, Emp-1, as a biomarker of gefitinib clinical resistance, and further suggests a 
probable cross-talk between this molecule and the EGFR signaling pathway 229,230. 
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Based on the above information and our microarray gene profiling experiments (table 3.15), 
most of the highlighted changes in gene expression upon selection for carboplatin resistance 
coded for proteins that protect cells from death by inhibiting apoptotic pathways. Therefore, 
inhibited apoptotic cell death may be one of the major mechanisms behind acquired carboplatin 
resistance in A2780DXLCBN cell lines. However, this needs to be confirmed using various tools 
that can monitor apoptosis induction and resistance.   
As we discussed above, acquired carboplatin resistance in A2780DXLCBN cell line may be 
caused by inhibiting apoptosis. While carboplatin resistance was established in A2780DXLCBN 
cells, the existing resistance to docetaxel was lost or partially lost in the cell line. There is thus 
some restoration of docetaxel sensitivity in A2780DXLCBN cells (Fig 3.5). The next question is 
why the same changes in gene expression that inhibit carboplatin-induced apoptosis could permit 
cell death via docetaxel? It is well known that carboplatin can act as a DNA crosslinker 24,29,231. 
It damages DNA, induces DNA repair and, ultimately induces apoptosis 232,233. Enhanced DNA 
repair and downregulated apoptotic pathways are main mechanisms for the resistance to 
carboplatin 216,234–236. On the other hand, taxanes target microtubules and cause mitotic arrest in 
the cells 217,218 . The mechanism of resistance to taxanes is mainly associated with increased drug 
efflux by ABC (ATP binding cassette) transporter family, especially Abcb1 (Chapter 1.3.4) 
218,237. In agreement with reported mechanism of resistance to taxanes, our results on microarray 
analysis (table 3.14) show that ABCB1 gene is down-regulated 28 times and ABCB4 is down-
regulated 131 times in A2780DXLCBN cell line comparing to A2780DXL cell line. This strongly 
suggests that decreased docetaxel efflux from cells is one of the main reasons for docetaxel 
resistance lost in A2780DXLCBN cell line.  As the result of decreased the drug efflux, there would 
be higher amounts of docetaxel accumulated in the cells while treating cells with docetaxel and 
90 
therefore higher cytotoxicity is observed. The reduction in ABCB1 expression would not enable 
more carboplatin accumulation in A2780DXLCBN cells, since carboplatin is not a substrate for the 
Abcb1 transporter.  A study has also suggested that high concentrations (0.2-30 M) of docetaxel 
can upregulate pro-apoptotic factor Bak and Bax and downregulate anti-apoptotic factor Bcl-XL 
75. Therefore apoptotic pathways contributing to docetaxel cytotoxicity may actually promote 
carboplatin resistance or vice versa.  However, this hypothesis must be confirmed by future 
experimentation. 
In our study, the A2780DXLCBN cell line acquired resistance to carboplatin, while existing 
docetaxel resistance was partially to fully lost. These findings support my hypothesis that 
sequentially exposing cells to a second drug permits restoration of sensitivity to the first drug to 
a greater extent than by simply removing exposure to docetaxel (selective pressure).  However, 
the establishment of the A2780CBNDXL resulted in retention of the original carboplatin 
resistance. This suggests that carboplatin resistance was established by a mechanism independent 
of the establishment of docetaxel resistance.  Similarly, during the so-called “drug free interval”, 
carboplatin resistance also stably persisted in the cells (A2780CBNCC), while docetaxel 
sensitivity can be partial to fully restored (A2780DXLCC).  
A2780CBNDXL (or CC)                        carboplatin resistance remains 
A2780DXLCBN                                   carboplatin resistance established 
A2780DXLCBN (or CC)                        docetaxel resistance is lost 
A2780CBNDXL                                   docetaxel resistance established 
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It appears that resistance to carboplatin is less reversible than docetaxel, meaning resistance to 
carboplatin may be a more stable phenotype (once achieved), while resistance to docetaxel is 
more “transient” and “reversible”.  
Permanent stable chromosomal alterations can take place, which are not easily reversed. This 
may particularly be the case for DNA damaging agents, such as cisplatin or carboplatin, 
compared to taxanes, although chromosomal alterations are also observed upon acquisition of 
docetaxel resistance (Reed et al., Epigenetics. 2008 Sep;3(5):270-80). A research group has 
provided evidence for alterations in gene copy number as a mechanism for chemo-resistance. 
They conducted molecular cytogenetic analysis of 23 chemo-resistance cancer cell lines, 8 of 
which were cisplatin resistant cell lines. Among those altered genes, 13 genes belong to ABC 
family and anti-apoptotic BCL-2 was consistently increased 238.  
BRCA1/2-deficient cancer cells are hypersensitive to DNA-crosslinking agents including 
cisplatin. Previous studies have shown that acquired cisplatin resistance can be mediated by 
secondary intragenic mutations in BRCA2 that restore the wild type BRCA2 reading frame in 
ovarian and breast carcinoma 239–241. Therefore, some of carboplatin resistance in the cell line 
may be caused by chromosomal alterations if the damage is permanent, then it would be non-
reversible. Glutathione and GST are related to detoxification of platinating agents. Another study 
confirmed at the genetic level that Glutathione S Transferase-π copy number is amplified when 
cells develop cisplatin resistance 127. 
These interesting phenomena may help provide guidance on approaches to improve clinical 
treatment for ovarian cancer patients using chemotherapy.  Carboplatin/docetaxel combination 
chemotherapy is now the standard regimen in the treatment of ovarian cancer.  Acquired 
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resistance to both agents will be established in most ovarian cancer cells after a period of 
treatment. However, as suggested by current study, the sensitivity to docetaxel can be partially or 
fully restored, if not co-administered with a platinating agent. Therefore, docetaxel may be 
subsequently readministered after a certain “drug free interval”, in particular after carboplatin 
treatment.  Thus, repeated sequential administration of docetaxel and carboplatin may lengthen 
the duration of useful clinical response than a single co-administration of the two agents. This 
could be assessed in clinical trials, providing the planned regimen can be expected to provide an 
equivalent or superior level of clinical response with equivalent or less toxicity.   
In this thesis, we have also documented the changes in gene expression, which accompany loss 
of previously established drug resistance with or without acquisition of resistance to a new 
chemotherapy agent.  However, more experiments need to be conducted to assess the relevance 
of these changes in gene expression in the above-described alterations in drug sensitivity.    
Confirmation of the changes in gene expression could be obtained by qPCR and western blotting 
experiments. Moreover, even if confirmed at the transcript or protein levels, post-transcriptional 
and post-translational events may ultimately impact on gene expression and drug sensitivity, for 
example, through the production of a non-coding RNAand/or the production of miRNAs.  In 
addition, splicing variants are possible that would not be detected by microarrays 242,243.  
Ultimately, we will then have to evaluate the clinical relevance of our findings through in vivo 
studies. 
This could  involve simulations of the in vivo microenvironment or  animal experiments. There 
are a lot of models to simulate the in vivo microenvironment, including multicellular tumour 
spheroids 244, multi-layered cell culture (MCC) on a permeable membrane support 97,245. In 
93 
animal tests, solid tumours can be transplanted into animal bodies to immerse in 
microenvironment. 
Finally, the above cultured cell lines represent a large collection of stable clones of cells 
surviving after selection and do not represent selection for a single clone of surviving cells that is 
subsequently propagated.  Therefore, it is unlikely that the differences observed between the 
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Appendix III Gene Expression Changes in A2780CBN-DXL vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 










































































































































































Appendix III Gene Expression Changes in A2780CBN-DXL vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 











































































































































































Appendix III Gene Expression Changes in A2780CBN-DXL vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 










































































































































































Appendix III Gene Expression Changes in A2780CBN-DXL vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 









































































































































































Appendix III Gene Expression Changes in A2780CBN-DXL vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 









































































































































































Appendix III Gene Expression Changes in A2780CBN-DXL vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 









































































































































































Appendix III Gene Expression Changes in A2780CBN-DXL vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 









































































































































































Appendix III Gene Expression Changes in A2780CBN-DXL vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 








































































































































































Appendix III Gene Expression Changes in A2780CBN-DXL vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 










































































































































































Appendix III Gene Expression Changes in A2780CBN-DXL vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 










































































































































































Appendix III Gene Expression Changes in A2780CBN-DXL vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 









































































































































































Appendix III Gene Expression Changes in A2780CBN-DXL vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 










































































































































































Appendix III Gene Expression Changes in A2780CBN-DXL vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 









































































































































































Appendix III Gene Expression Changes in A2780CBN-DXL vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 










































































































































































Appendix III Gene Expression Changes in A2780CBN-DXL vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 









































































































































































Appendix III Gene Expression Changes in A2780CBN-DXL vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 










































































































































































Appendix III Gene Expression Changes in A2780CBN-DXL vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 









































































































































































Appendix III Gene Expression Changes in A2780CBN-DXL vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 









































































































































































Appendix III Gene Expression Changes in A2780CBN-DXL vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 










































































































































































Appendix III Gene Expression Changes in A2780CBN-DXL vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 









































































































































































Appendix III Gene Expression Changes in A2780CBN-DXL vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 









































































































































































Appendix III Gene Expression Changes in A2780CBN-DXL vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 











































































































































































Appendix III Gene Expression Changes in A2780CBN-DXL vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 








































































































































































Appendix III Gene Expression Changes in A2780CBN-DXL vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 








































































































































































Appendix III Gene Expression Changes in A2780CBN-DXL vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix III Gene Expression Changes in A2780CBN-DXL vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 












Appendix IV Gene Expression Changes in A2780CBN-CC vs. A2780CC (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix IV Gene Expression Changes in A2780CBN-CC vs. A2780CC (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix IV Gene Expression Changes in A2780CBN-CC vs. A2780CC (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix IV Gene Expression Changes in A2780CBN-CC vs. A2780CC (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix IV Gene Expression Changes in A2780CBN-CC vs. A2780CC (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix IV Gene Expression Changes in A2780CBN-CC vs. A2780CC (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix IV Gene Expression Changes in A2780CBN-CC vs. A2780CC (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix IV Gene Expression Changes in A2780CBN-CC vs. A2780CC (FDR=0.01, p≤0.05, variation ≥2-fold) 






































Appendix V Gene Expression Changes in A2780DXL-CBN vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 








































































































































































Appendix V Gene Expression Changes in A2780DXL-CBN vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 









































































































































































Appendix V Gene Expression Changes in A2780DXL-CBN vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 










































































































































































Appendix V Gene Expression Changes in A2780DXL-CBN vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 









































































































































































Appendix V Gene Expression Changes in A2780DXL-CBN vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 








































































































































































Appendix V Gene Expression Changes in A2780DXL-CBN vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 








































































































































































Appendix V Gene Expression Changes in A2780DXL-CBN vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 









































































































































































Appendix V Gene Expression Changes in A2780DXL-CBN vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 








































































































































































Appendix V Gene Expression Changes in A2780DXL-CBN vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 










































































































































































Appendix V Gene Expression Changes in A2780DXL-CBN vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 









































































































































































Appendix V Gene Expression Changes in A2780DXL-CBN vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 








































































































































































Appendix V Gene Expression Changes in A2780DXL-CBN vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 











































































































































































Appendix V Gene Expression Changes in A2780DXL-CBN vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 















































































































































































Appendix V Gene Expression Changes in A2780DXL-CBN vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 









































































































































































Appendix V Gene Expression Changes in A2780DXL-CBN vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 









































































































































































Appendix V Gene Expression Changes in A2780DXL-CBN vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 




















































Appendix VI Gene Expression Changes in A2780DXL-CC vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VI Gene Expression Changes in A2780DXL-CC vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VI Gene Expression Changes in A2780DXL-CC vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VI Gene Expression Changes in A2780DXL-CC vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VI Gene Expression Changes in A2780DXL-CC vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VI Gene Expression Changes in A2780DXL-CC vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VI Gene Expression Changes in A2780DXL-CC vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 








































































































































































Appendix VI Gene Expression Changes in A2780DXL-CC vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VI Gene Expression Changes in A2780DXL-CC vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VI Gene Expression Changes in A2780DXL-CC vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VI Gene Expression Changes in A2780DXL-CC vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VI Gene Expression Changes in A2780DXL-CC vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VI Gene Expression Changes in A2780DXL-CC vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VI Gene Expression Changes in A2780DXL-CC vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VI Gene Expression Changes in A2780DXL-CC vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VI Gene Expression Changes in A2780DXL-CC vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VI Gene Expression Changes in A2780DXL-CC vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VI Gene Expression Changes in A2780DXL-CC vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VI Gene Expression Changes in A2780DXL-CC vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VI Gene Expression Changes in A2780DXL-CC vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VI Gene Expression Changes in A2780DXL-CC vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VI Gene Expression Changes in A2780DXL-CC vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VI Gene Expression Changes in A2780DXL-CC vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 








































































































































































Appendix VI Gene Expression Changes in A2780DXL-CC vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VI Gene Expression Changes in A2780DXL-CC vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VI Gene Expression Changes in A2780DXL-CC vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VI Gene Expression Changes in A2780DXL-CC vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VI Gene Expression Changes in A2780DXL-CC vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VI Gene Expression Changes in A2780DXL-CC vs. A2780DXL (FDR=0.01, p≤0.05, variation ≥2-fold) 




































































Appendix VII Gene Expression Changes in A2780DXL-CBN vs. A2780CBN (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VII Gene Expression Changes in A2780DXL-CBN vs. A2780CBN (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VII Gene Expression Changes in A2780DXL-CBN vs. A2780CBN (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VII Gene Expression Changes in A2780DXL-CBN vs. A2780CBN (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VII Gene Expression Changes in A2780DXL-CBN vs. A2780CBN (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VII Gene Expression Changes in A2780DXL-CBN vs. A2780CBN (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VII Gene Expression Changes in A2780DXL-CBN vs. A2780CBN (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VII Gene Expression Changes in A2780DXL-CBN vs. A2780CBN (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VII Gene Expression Changes in A2780DXL-CBN vs. A2780CBN (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VII Gene Expression Changes in A2780DXL-CBN vs. A2780CBN (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VII Gene Expression Changes in A2780DXL-CBN vs. A2780CBN (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VII Gene Expression Changes in A2780DXL-CBN vs. A2780CBN (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VII Gene Expression Changes in A2780DXL-CBN vs. A2780CBN (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VII Gene Expression Changes in A2780DXL-CBN vs. A2780CBN (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VII Gene Expression Changes in A2780DXL-CBN vs. A2780CBN (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VII Gene Expression Changes in A2780DXL-CBN vs. A2780CBN (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VII Gene Expression Changes in A2780DXL-CBN vs. A2780CBN (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VII Gene Expression Changes in A2780DXL-CBN vs. A2780CBN (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VII Gene Expression Changes in A2780DXL-CBN vs. A2780CBN (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VII Gene Expression Changes in A2780DXL-CBN vs. A2780CBN (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VII Gene Expression Changes in A2780DXL-CBN vs. A2780CBN (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VII Gene Expression Changes in A2780DXL-CBN vs. A2780CBN (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VII Gene Expression Changes in A2780DXL-CBN vs. A2780CBN (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VII Gene Expression Changes in A2780DXL-CBN vs. A2780CBN (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VII Gene Expression Changes in A2780DXL-CBN vs. A2780CBN (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VII Gene Expression Changes in A2780DXL-CBN vs. A2780CBN (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VII Gene Expression Changes in A2780DXL-CBN vs. A2780CBN (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VII Gene Expression Changes in A2780DXL-CBN vs. A2780CBN (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VII Gene Expression Changes in A2780DXL-CBN vs. A2780CBN (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VII Gene Expression Changes in A2780DXL-CBN vs. A2780CBN (FDR=0.01, p≤0.05, variation ≥2-fold) 















Appendix VIII Gene Expression Changes in A2780DXL-CC vs. A2780CC (FDR=0.01, p≤0.05, variation ≥2-fold) 






































































































































































Appendix VIII Gene Expression Changes in A2780DXL-CC vs. A2780CC (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VIII Gene Expression Changes in A2780DXL-CC vs. A2780CC (FDR=0.01, p≤0.05, variation ≥2-fold) 








































































































































































Appendix VIII Gene Expression Changes in A2780DXL-CC vs. A2780CC (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VIII Gene Expression Changes in A2780DXL-CC vs. A2780CC (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VIII Gene Expression Changes in A2780DXL-CC vs. A2780CC (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VIII Gene Expression Changes in A2780DXL-CC vs. A2780CC (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VIII Gene Expression Changes in A2780DXL-CC vs. A2780CC (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VIII Gene Expression Changes in A2780DXL-CC vs. A2780CC (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VIII Gene Expression Changes in A2780DXL-CC vs. A2780CC (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































Appendix VIII Gene Expression Changes in A2780DXL-CC vs. A2780CC (FDR=0.01, p≤0.05, variation ≥2-fold) 






















































































Appendix IX 435 Gene Expression Changes representing docetaxel resistance establishment in A2780CBN-DXL cell line 
 (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































































Appendix IX 435 Gene Expression Changes representing docetaxel resistance establishment in A2780CBN-DXL cell line 
 (FDR=0.01, p≤0.05, variation ≥2-fold) 







































































































































































































Appendix IX 435 Gene Expression Changes representing docetaxel resistance establishment in A2780CBN-DXL cell line 
 (FDR=0.01, p≤0.05, variation ≥2-fold) 

















































Appendix X 1319 Gene Expression Changes representing carboplatin resistance establishment in A2780DXL-CBN cell line 
 (FDR=0.01, p≤0.05, variation ≥2-fold) 




































































































































































































Appendix X 1319 Gene Expression Changes representing carboplatin resistance establishment in A2780DXL-CBN cell line 
 (FDR=0.01, p≤0.05, variation ≥2-fold) 




































































































































































































Appendix X 1319 Gene Expression Changes representing carboplatin resistance establishment in A2780DXL-CBN cell line 
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Appendix X 1319 Gene Expression Changes representing carboplatin resistance establishment in A2780DXL-CBN cell line 
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                     Gene name      Fold change              Gene name   Fold change             Gene name   Fold change               Gene name   
Fold change 
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NR2F2 -7.3 
FAM5C -7.4 
CR936711 -7.6 
ME1 -7.6 
RERG -7.6 
THC2512148 -7.8 
SC5DL -7.8 
STAMBPL1 -7.8 
HAND2 -7.9 
CITED2 -8.0 
CTSF -8.1 
RGS20 -8.3 
P2RX5 -8.4 
ZDBF2 -8.6 
TMCO4 -8.6 
IDO1 -8.7 
RBM47 -8.7 
SLC38A5 -8.8 
CEP44 -8.8 
GPC4 -8.9 
TP53TG1 -9.0 
IFI27L2 -9.2 
METTL7A -9.3 
CHRNA3 -9.5 
GLIS1 -9.5 
AB014766 -9.7 
GCH1 -9.7 
RIN2 -10.1 
CYB5R2 -10.1 
ENST00000462693 -10.6 
FAS -10.9 
SESN3 -10.9 
ICA1 -10.9 
MMRN1 -11.0 
SP5 -11.0 
FERMT1 -11.3 
NFIA -11.6 
FUT4 -11.8 
MCF2 -12.4 
AF100640 -12.4 
PDE6H -12.5 
EPCAM -12.6 
EFHC2 -13.0 
L3MBTL3 -13.4 
TLE1 -13.4 
LOC100505806 -13.5 
SCIN -14.2 
RBM20 -15.4 
LOC100132593 -15.7 
SFRP1 -15.8 
EFNB2 -15.9 
LMO4 -16.0 
SYNE1 -16.1 
KRT80 -16.4 
THC2646628 -17.3 
GSTO2 -17.8 
ATRNL1 -19.4 
HYLS1 -19.4 
EPHX2 -19.8 
DNAJC12 -20.1 
PPP4R4 -21.0 
CDCA7L -21.5 
PTPRK -21.7 
CDH2 -22.0 
ARHGDIB -22.2 
HAPLN1 -22.4 
GAD1 -22.5 
CELF2 -22.5 
C8orf4 -22.7 
MDK -22.9 
IGF1R -23.1 
CGREF1 -23.8 
SGCE -23.8 
PDZRN4 -24.2 
BF217859 -24.6 
PAX6 -24.9 
RARB -25.3 
CYB5A -25.5 
GLCCI1 -25.6 
HTATIP2 -25.7 
THC2535223 -25.8 
TMPRSS15 -25.9 
TOX -26.6 
RERGL -27.3 
KANK1 -27.8 
PLAC8 -28.5 
DOK6 -28.5 
EDIL3 -28.6 
MLH1 -30.1 
PEG10 -30.4 
ABCA5 -31.8 
LUM -34.1 
GPM6B -39.8 
NTS -40.2 
HECA -42.2 
FAM198B -43.5 
ASB9 -46.2 
DMRT3 -50.7 
BEX2 -53.8 
STXBP5L -54.2 
LRP1B -59.5 
DCN -61.9 
MGAT4C -65.8 
VGLL3 -72.9 
RASSF9 -73.3 
CHRNA9 -77.0 
BEX1 -138 
PCDH20 -252 
 
